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Abstract 
Propolis, bee venom and bee pollen all have been used by humans traditionally for various 
medicinal purposes. Studies of these products have been limited primarily to antimicrobial, 
antifungal, anticancer and free radical scavenging properties. The mechanisms of action of 
these products remain largely unknown. This study investigates the biological effects of 
propolis, bee venom and bee pollen using chemical genomics and the yeast model organism. 
These products are screened against genome-wide yeast mutant libraries to determine the 
genes, proteins, and pathways that are targets of these products. I identified that propolis 
chelates iron and consequently creates an iron-deficient condition, which results in the 
upregulation of plasma membrane and vacuolar high-affinity iron transporters to maximise 
iron acquisition. Bee venom inhibited the biosynthesis of phosphatidylcholine via Opi3p that 
catalyses the final two steps of phosphatidylcholine biosynthesis within the CDP-
ethanolamine pathway. Bee pollen showed a potential effect on GDP-mannose transport in 
which the GDP-mannose transport mutants confer hypersensitivity against bee pollen 
treatment.  
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1.0 Introduction 
1.1 Natural products demand as health food and therapeutic treatment  
Since ancient times, humans have relied on the use of natural resources 
for treatment of diseases. A common misconception of historical medicinal 
practices is that our ancestors picked a random assortment of natural resources, 
be it plants, animal or even earth materials to make a concoction and administer 
it toward the sick. In fact, there is strong historical evidence of rational medicinal 
practices based on empirical methods (Alkhateeb, 2014; Borchardt, 2002). With 
the rich knowledge of natural products as source of medicine, the collective 
knowledge of the therapeutic benefit of the natural products is far from 
complete. Moreover, natural products still possess demand in developing 
countries and approximately half of modern medicines are derived from natural 
products (Cragg & Newman, 2013). 
 
1.2 Bee products’ therapeutic use and pharmacological benefits  
1.2.1 Propolis  
 Propolis is an accumulation of balsamic resins from plant leaf buds and 
barks (Ghisalberti, 1979). As it is a collection of resins, the constituents of its 
composition are found to vary according to season and geographical location 
(Brown, 1989; Khalil, 2006). It has two natural uses by the honey bees; as a cement 
to repair and protect the hive and as an antiseptic for the protection of their larvae, 
honey and combs (Seeley & Morse, 1976).  
10 
 
 The historical uses of propolis can be traced back to the time of the greeks, 
Egyptians, persians and romans where it has been used to cure external and 
internal wounds and ulcers, painkillers, treating inflammations (Kuropatnicki et al., 
2013).To this day, propolis is widely used by practictioners of alternative medicine 
and administered in different forms primarily as an antiseptic. Among common 
applications being as ointments for treating external injuries and inflammations 
and throat lozenge (Castaldo & Capasso, 2002). A number studies that explores 
biological effects of propolis. Among them is the antimicrobial and antifungal 
properties of propolis (Elbaz & Elsayad, 2012; Pavilonis et al., 2008; Ozen et al., 
2010; Quiroga et al., 2006). There are studies that demonstrated efficacy of 
propolis as antioxidants and also as tumour suppressing properties (Valente et al., 
2011; Li et al., 2007). There are studies that showed how propolis suppressed 
cancer cell lines and induced apoptosis in fungi (Valente et al., 2011; Castro et al., 
2011). However, the mechanism of selective cancer cell suppression and apoptosis 
induction were unknown to whether the apoptosis was being induced directly or 
that apoptosis was a consequence of physiological changes caused by propolis. 
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1.2.2 Bee Venom 
Bee venom is traditionally used topically to treat skin diseases and orally 
to treat arthritis, rheumatism, and cancer (Hider, 1988). The main bioactive 
compounds of bee venom are melittin, apamin, adolapin and phospholipase A 
(Lariviere & Melzack, 1996). Melittin, the main active component of bee venom 
is found to induce leak to phospholipid bilayer (Pratt et al., 2005) and found to 
exhibit cytotoxicity on a myriad of cancer cell lines by triggering both intrinsic 
and extrinsic apoptosis without inducing cytoxicity on normal cells via selectively 
targeting activated ras oncogenes (Orsolic, 2012; Moon et al., 2006; Jp et al., 
2012). Also, it is found that melittin can suppress free radical production via 
calmodulin (Son et al., 2007). Adolapin is the component that contributes to anti-
inflammatory effect of bee venom. 
Bee venom has been used in acupuncture, a new alternative therapy 
termed Bee venom acupuncture. Such therapy has found to reduce and prevent 
arthritic inflammation when performed in rats (Kwon et al., 2002; Lee et al., 
2005). The anti-inflammatory effect of bee venom is mediated via inhibition of 
iNOS activity and iNOS mRNA expression, and TNF-α production which is 
contributed by the water soluble fraction comprised of melittin, adolapin, mast 
cell degranulating (MCD) peptide and phospholipase A (Kwon et al., 2002; Han 
et al., 2007). Another study demonstrated that bee venom can suppress 
inflammatory factors and reverse stimulation by inflammatory agent (Yin et al., 
2005). Bee venom is also found to exhibit antimicrobial and antifungal effects in 
numerous studies (Yu et al., 2006; Fennel et al., 1968). Although growth 
inhibition of various bacterial and fungal species was demonstrated, it remains 
12 
 
unclear whether bee venom directly induces pro-apoptotic signal or alters 
physiology that leads to apoptosis. 
 
 
1.2.3 Bee Pollen 
Bee pollen refers to the pollen dust which the bees accumulate on their body 
when collecting nectar (Bruno, 2005). For the honey bees, bee pollen serves as a 
source for proteins, fats and minerals (Villanueva et al., 2002). Similarly to propolis, 
the constituents of bee pollen is location- and season-dependent (Campos et al., 
2008). For example, bee pollen products from different regions possess different 
therapeutic effects. The pollen was used by physicians as early as the 12th century 
and was used increasingly after the development of pollen traps (Bogdanov, 2014).   
Although the therapeutic mechanisms of bee pollen are largely unknown, 
bee pollen is sold to consumers as health food with therapeutic effects including 
hepatoprotective and anti-inflammatory properties (Pascoal et al., 2014) 
(Maruyama et al., 2010). In addition, bee pollen improved digestion (Wojckiki et 
al., 1986; Wojciki et al., 1985; Wang et al., 2007). Other benefits which bee pollen 
was found to possess are antioxidative properties and antimicrobial properties 
(Fatrcova-Sramkova et al., 2013). However, how bee pollen achieved these 
therapeutic benefits in cellular level had not been investigated. 
 
.  
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1.3 Yeast as model organism  
1.3.1 Advantage of using yeast as model organism 
Yeast (Saccharomyces cerevisiae) is well suited to study the mechanism of 
action of bioactive compounds. Yeast genes and proteins were conserved 
(Tugendreich et al., 1994). The data of the compound activity on yeast can be 
translated into other eukaryote subjects to a good degree. The yeast genome is 
well characterised and the compendium of information of genes known to yeast 
is available in Saccharomyces Genome Database (SGD; 
http://www.yeastgenome.org). Furthermore, yeast is the only organism with a 
genome-wide range of deletion strains available and this is attributed to the 
feasibility of genetic manipulation of the yeast genome (Nislow & Giaever, 2007).   
 
1.3.2 Ability to elucidate bioactivity on non-essential and essential genes 
The development of the yeast deletion strain library allowed for precise 
genetic studies of molecular mechanisms of compounds (Winzeler et al., 1999). 
The use of deletion strain library for profiling a compound’s mechanism of action 
has been demonstrated by identifying mutant strains which exhibit 
hypersensitivity, thus creating a chemical genetic profile for the bioactive 
compounds (Giaever et al., 1999; Glaever et al., 2002; Glaever et al., 2004; Parsons 
et al., 2004). Chemical genetic profiling adapts the principle of synthetic lethality. 
Synthetic lethality is a phenomenon in which two single null mutations produce 
viable organisms when it occurs separately but produce inviable organisms when 
both mutations occur together (Figure 1A) (Parsons et al., 2004; Hartman et al., 
2001). It is found that the majority of the non-essential genes have synthetically 
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lethal interaction with another one or two genes and with the most with 26 genes 
(Hartman et al., 2001). This would mean that these genes, which are coined “non-
essential” genes have other redundant genes that carry out the same process but 
via distinct and compensatory pathways. Synthetic Genetic Array (SGA) analysis 
creates synthetic lethal screens by mating MATα haploid yeast query mutants with 
the MATa haploid yeast deletion library which identifies the molecular function of 
the deleted genes and thus mapping the genetic interaction network (Tong et al., 
2001). This allows identification of the functions of the non-essential genes.  
In order to characterise the essential genes, which are genes that cause 
inviability upon deletion, a library called the decreased abundance by mRNA 
perturbation (DAmP) library was constructed (Schuldiner et al., 2005). This library 
of mutant essential genes is the alternative to using inducible gene inactivation via 
conditional protein disruption, transcriptional shut-off, or a heterozygous diploid 
mutant library that essentially reduces the gene dosage to 50% (Giaever et al., 
1999). On the other hand, the DAmP library was constructed by inserting an 
antibiotic resistance cassette into 3’ untranslated region of an essential gene, thus 
disrupting the mRNA transcription process and leading to lower amount of mRNA 
production while ensuring these yeast strains remain viable (Breslow et al., 2008). 
The advantage of the DAmP library over the other methods of characterising 
essential genes is that the essential gene disruption does not cause severe steady-
state growth defects making analysis difficult.  
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1.3.3 Feasibility of yeast to elucidate biological activity  on protein expression and 
localisation 
Another significant advantage of yeast as compared to other model 
organisms is the availability of the green fluorescent-tagged protein (GFP) library. 
This library was generated by insertion of GFP sequence to the 3’ end of the 
desired open reading frame (ORF), creating a fusion protein with green 
fluorescence (Huh et al., 2003). This enabled observation of localisation of the 
proteins and quantification of the amount of fluorescence (protein expression). 
These measurements of localization and quantification correlated with the 
amount of protein measured using flow cytometry (Newman et al., 2006) and 
confocal microscopy (Carter et al., 2008). 
 
1.4 Chemical Genetics to elucidate bee products mode of action in yeast 
Chemical genetics is the most common method used to elucidate 
bioactive compounds’ mechanism of action. The core principle of chemical 
genetics is that a compound acts upon the model organism to mimics a mutation 
(Parsons, et al., 2004).  Employing the same principle of synthetic lethality to 
characterise a gene function, the compound can act as a secondary mutation to 
the existing deletion or suppressed strains. Thus, the strains sensitive to the 
compound treatment suggest the particular biological processes affected by the 
compound (Figure 1.1b, Parsons et al., 2004). Combination of ~4800 non-
essential deletion mutants strains (Parsons et al., 2004) and 837 DAmP 
(Schuldiner et al., 2005) strains libraries provides extensive coverage of the yeast 
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genome of 6200 genes hence allowing thorough characterisation of a 
compound’s mode of action. Adding compound screening against yeast GFP 
library gives further idea of whether the impact of compound is affecting the 
expression of such proteins or hindering the activity of the affected proteins.  
 
 
 
Figure 1.1. Chemical genetic can reproduce a synthetic lethal interactions. (A) A 
synthetic lethal interaction where deletion of two genes separately results in viable 
individuals whereas the combination of both genes being deleted results in inviable 
individual. (B) Chemical genetic interactions where certain particular gene deletion that 
is viable becomes inviable when treated with a bioactive compound at sub-lethal 
concentration which would not cause inviability to the wildtype.   
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The chemical-genetic profiling is not restricted to screening one pure 
compound at a time but can accommodate a mixture of compounds for 
screening simultaneously. This is attractive when studying the nutritional effect 
of diet to the cell’s physiology. The rationale for using the mixture is that the bee 
products has been used in its raw form. These raw forms, similar to any other 
raw natural products, consist of different bioactives and proteins which may 
work synergistically to give its desired effect. Our aim is to employ chemical 
genetic screens of the discussed extracts against the yeast haploid deletion strain 
library to assess the genetic target of these extracts thus, evaluating the claims 
of the use of these extracts and identify their other potential effects. 
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2.0 Methods and Materials  
2.1 Yeast strains 
S. cerevisiae strains used in this thesis are as follows: 
 
Strain Genotype 
BY4741 MATa his3∆1 leu2∆0 met15∆0 
ura3∆0 
∆xxx MATa xxx∆::kanR; his3∆1 leu2∆0 
met15∆0 ura3∆0 
XXX-GFP MATa XXX-GFP::natR leu2∆0 ura3∆0 
met15∆0  
xxx-DAmP MATa xxx-DAmP::kanR; his3∆1 
leu2∆0 met15∆0 ura3∆0 
 
Our yeast homozygous deletion library and DAmP library were purchased from 
OpenBiosystems. Other than BY4741, other strains are representative of 
respective yeast libraries. 
2.2 Growth media and components 
S. cerevisiae strains were all cultured in one of the following growth 
media either in agar or in broth form. Appropriate antibiotics were also 
supplemented to the media; final concentration of 200 µg/ml geneticin (G418) 
for yeast deletion and DAmP library collection, 100 µg/ml ClonNAT (Werner 
bioAgents) and 20 µg/ml Hygromycin (Werner bioAgents) for yeast GFP 
collection.  
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Yeast peptone dextrose (YPD) agar: 1% (w/v) yeast extract (Becton, Dickinson and 
Company), 2% (w/v) bacto-peptone (Becton, Dickinson and Company), 0.12% 
(w/v) adenine (Sigma-Aldrich), 2% (w/v) glucose (Sigma-Aldrich) and 2% (w/v) g 
agar (Invitrogen). YPD broth was prepared without agar addition. 
HEPES –buffered synthetic complete (SC+HEPES) agar: 0.17% (w/v) yeast nitrogen 
base without amino acids or ammonium sulphate (Becton, Dickinson and 
Company), 0.1% (w/v) monosodium glutamate (Sigma-Aldrich), 0.2% (w/v) amino 
acid mixture to suit (Sigma-Aldrich), 20mM HEPES (Fisher Bioreagents), 2% (w/v) 
agar (Becton, Dickinson and Company) and 2% (w/v) glucose (Sigma-Aldrich). SC 
broth was prepared without agar addition. 
Synthetic dropout (SD) agar: As with SC minus the addition of appropriate amino 
acid. SD broth was prepared without agar addition. 
Amino acids mixture for SC media: 3g adenine, 2 g uracil, 2g inositol, 0.2 g para-
aminobenzoic acid, 2 g alanine, 2g asparagine, 2 g aspartic acid, 2 g cysteine, 2 g 
glutamic acid, 2 g glutamine, 2 g glycine, 2 g histidine, 2 g isoleucine, 10 g leucine, 
2 g lysine, 2 g methionine, 2 g phenylalanine, 2 g proline, 2 g serine, 2 g threonine, 
2 g tryptophan, 2 g tyrosine and 2 g valine. 
SD amino acid mixture prepared in this thesis is a mixture of amino acids 
(Invitrogen) above minus 2 g histidine (SD-His). 2 g of this mixture is added in 
preparation of 1L broth or agar media. 
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2.3 Preparation of bee products 
2.3.1 Preparation of propolis extract 
Propolis was obtained from GoHealthy in the form of gelatin capsules 
containing a viscous liquid. Propolis (10 g) was dissolved in 30ml water and 
incubated overnight at 30°C in a shaking incubator. Propolis was then 
centrifuged at 16, 000 g for 20 minutes and filtered through 0.22nm pore size 
filter. The filtrate was labelled “crude propolis” and the residue was resuspended 
in 30ml methanol and incubated overnight at 30°C in shaking incubator. The 
methanolic propolis was centrifuged at 16, 000 g for 20 minutes and filtered 
through 0.22nm pore size filter. The filtrate was collected and the methanol was 
evaporated from the methanolic extract of propolis using Labconco Centrivap -
50 cold trap machine. The methanolic extract residue was resuspended in 100% 
DMSO. The treatment condition of crude and methanolic extracts of propolis was 
completed as the percentage of volume of propolis in total volume of media (% 
v/v). 
 
2.3.2 Preparation of bee pollen extract  
Bee pollen was purchased from GoHealthy in the form of small granules 
within gelatin capsules. Pollen (1g) was dissolved in 40ml 100% DMSO and 
incubated overnight at 30°C in a shaking incubator. The extract was then 
centrifuged at 16, 000 g for 20 minutes and filtered through 0.22nm pore size 
filter. The filtrate was labelled “crude pollen” and the pellet was resuspended in 
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30ml methanol and incubated overnight at 30°C in a shaking incubator. The 
methanolic pollen was centrifuged at 16, 000 g for 20 minutes and filtered 
through 0.22nm pore size filter. We collected the filtrate and evaporated off the 
methanol from the methanolic extract of pollen using cold trap machine. The 
methanolic extract residue was resuspended in 100% DMSO. The treatment 
condition of the crude and methanolic extracts of bee pollen was completed as 
the percentage of volume of bee pollen in total volume of media (% v/v). 
 
2.3.3 Preparation of bee venom  
Bee venom was obtained from HoneyLab Ltd. Bee venom (0.1438g) was 
dissolved in 12 ml of water, vortexed at 1000 rpm for 5 minutes, and filtered 
through 0.22 nm syringe filter. The filtrate was collected and stored at -20°C. The 
treatment condition of bee venom was completed as the volume of bee venom 
stock (µl) in 1ml of media (µl/ml).  
 
2.4 Dose response studies 
2.4.1 Propolis and bee pollen broth dose response. 
We prepared a fresh streak of BY4741 yeast strain from our frozen stock 
from the -80°C freezer and incubate them overnight. We inoculated a fresh 
streak of BY4741 yeast strain in 2ml SC broth and incubated the broth at 30°C 
overnight. We measured the absorbance of the overnight yeast culture and 
made a yeast stock at an OD600 of 0.1 for inoculation.  
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We prepared a 96-well microtiter plate with each well containing 194µl 
of either media containing propolis or bee pollen at a range of concentrations. 
Each concentration was prepared in triplicate. We inoculated 6 µl of yeast on 
each well but some wells that will be used as blanks. We incubated the plate at 
30°C and measured the absorbance at OD600 of the wells of the plate at 16 and 
24 hours. The absorbance of each well was averaged across the corresponding 
triplicate and was normalised by subtracting the averaged value with the 
averaged value of the blanks. We analysed the absorbance by comparing the 
absorbance of the treated wells with the untreated control wells in the form of 
percentage termed “residual growth”. The residual growth was calculated as 
follows: 
Residual Growth (%) = 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑎𝑣𝑒𝑟𝑎𝑔𝑒𝑑 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑒𝑙𝑙𝑠
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑤𝑒𝑙𝑙𝑠
 X 100% 
To study whether the concentrations of each bee product were simply 
growth inhibitory or toxic (killing the yeast), we performed another dose 
response using the same format as mentioned before but only at minimum 
inhibitory concentrations (MIC) which is the minimum concentration stop cell 
growth completely. After 2 hours and 6 hours of treatment with the respective 
bee products, we inoculated 30µl of each well on YPD agar. We incubated the 
agar plate at 30°C overnight and photographed the agar plate. 
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2.4.2 Bee venom broth dose response  
 Bee venom liquid dose response procedure was optimised for performing 
chemical genomic profiling of bee venom against both homozygous deletion 
library and DAmP library. With the streaked BY4741 prepared in 2.4.1, we 
inoculated the BY4741 strain into 5 ml of YPD broth media, incubated overnight 
in 30°C incubator with rotation, added 15ml of sterile water, vortexed, and 
aliquoted 200µl of the mixture into each well of a 96-well microtiter plate. We 
inoculated the yeast from the 96-well plate onto a fresh YPD agar plate and the 
agar plate was grown for 2 days in 30°C incubator. We then inoculated the YPD 
agar plate in 96 colony format into a 96-well microtiter plate containing 200µl 
SC+HEPES. We placed the microtiter plate in 30°C incubator for 24 hours.  The 
following day, we prepared a new microtiter plate containing 200µl of SC+HEPES 
broth media with different concentrations of bee venom. We ensured each 
treatment condition was made in triplicate. We inoculated the yeast from the 
cultured 96-well microtiter plate into 96-well microtiter plate with various bee 
venom treatment conditions. We measured the absorbance at 590nm (OD590) 
using immediately after inoculation as our 0th hour. We let the yeast grow 
overnight inside 30°C incubator and measured absorbance at 16 and 24 hours. 
We normalised the OD590 reading by deducting the absorbance of each well of 
the 16th and 24th hours’ OD590 with the 0th hour OD590.  
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2.4.3 Propolis / bee venom / bee pollen agar dose response. 
The yeast stock was prepared the same way as yeast stock from broth 
dose response but with two additional stocks that were one-tenth and one-
hundreth of the first prepared stock. We prepared a 24-well plate with each well 
containing 500µl SC+HEPES agar with or without treatment of propolis, bee 
venom or bee pollen at specified concentrations. We inoculated 1µl of each yeast 
stock onto each well, incubated the plate at 30°C for 48 hours, and photographed 
the 24-well plate at 24 and 48 hours.  
We further optimised the concentration of propolis and bee pollen for 
1536 yeast colony array format by preparing different treatment conditions of 
bee pollen and propolis in 40ml SC+HEPES agar contained in Singer plates. We 
used Singer Rotor HDA to inoculate yeast from a plate from the homozygous 
deletion library onto each 40ml SC+HEPES agar conditions. We grew the 
inoculated plates in 30°C incubator and photographed each plate at 24 hours. 
The colony size is then measured and analysed as described in 2.5.2 
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2.5 Homozygous deletion library and DAmP library yeast colonies screening & 
image acquisition analysis 
 
2.5.1 Homozygous deletion library and DAmP library yeast colonies screening 
 We prepared 40ml SC + HEPES agar media with containing 1% v/v propolis or 2% 
v/v bee pollen. We also prepared similar set of SC + HEPES agar media with 
equivalent amount of DMSO as solvent control. Each treated plates are in triplicate. 
We used Singer Rotor HDA to pin from our 1536 array homozygous deletion library 
and DAmP library onto the experimental plates. The inoculated plates are grown 
at 30°C and the plates were photographed after 24 hours. 
 
2.5.2 1536-colonies array analysis  
Yeast in 1536-colonies array format were used in the screening step. This array 
allows for four replicates of each mutant strains in each Singer plate. We used R 
“Gitter” software package to measure the mutant yeast colony size in 1536-array 
format in Singer plate (Wagih & Parts, cran-r-project.org, 2014). Gitter generate 
a .DAT format data accessible using Excel 2013 from our photographed yeast 
plates. We modified the format of the files to make log files of the containing 
colony sizes of all Boone library plates and their triplicates under solvent 
treatment and the other triplicates under extract treatment. We uploaded the log 
file onto Rothstein Lab’s Data Review Engine to analyse colonies and provides 
statistical assessment of the colony size differences under solvent treatment in 
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comparison to extract treatment (Dittmar et al., 2010). The Data Review Engine 
provides us with the growth ratio of each mutant and their corresponding p-values 
which we used to pick as sensitive or resistant strains. The growth ratio was 
measured as follows: 
Growth ratio = 
𝐶𝑜𝑙𝑜𝑛𝑦 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑦𝑒𝑎𝑠𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑡𝑟𝑎𝑖𝑛
𝐶𝑜𝑙𝑜𝑛𝑦 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑦𝑒𝑎𝑠𝑡 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑡𝑟𝑎𝑖𝑛
  
 
  2.5.3 Propolis and bee pollen agar validation 
The validation step is performed to verify hits that were obtained from 
our library screens. This step is crucial to eliminate false hits and thus ensuring 
the reproducibility of hits obtained .We prepared a set of SC+HEPES agar in petri 
dishes at concentration range of 0.03-1 % v/v. We grew deletion strains which 
were hits from the homozygous deletion and DAmP library screening each in 2ml 
SC+HEPES broth in 30°C incubator with rotation. We used a 96-well microtiter 
plate to prepare wells containing 1 x 106 cells/ml and diluted down at 1:10 
dilution in subsequent wells up until the sixth wells. Using multi-channel pipette, 
we blotted 1µl of each strain and its subsequent dilution from the microtiter 
plate onto the petri dishes containing propolis or bee venom at specified 
concentrations and petri dishes containing SC+HEPES and equivalent amount of 
DMSO. We incubated the petri dishes for 48 hours and photographed the yeast 
colonies. We chose a concentration for assessment based on the highest possible 
concentration that did not inhibit the growth of our BY4741 wildtype strain.  
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2.5.4 Bee venom broth library screening and validation 
We inoculated cells from our frozen stock of homozygous deletion library 
and DAmP library onto YPD + Geneticin agar media. We grew the agar plates in 
30°C overnight and inoculated yeast colonies from the grown agar media onto 
96-well microtiter plate containing SC+HEPES 200µl media broth and incubated 
overnight. We inoculated yeast from the overnight broth into the prepared 96-
well microtiter plates containing 200µl SC+HEPES media either with or without 
0.1µl/ml bee venom. Each strain treatment was done in triplicate. We incubated 
the plates at 30°C and measured the absorbance at OD590 after 16 and 24 hours 
post-inoculation. The absorbance reading was averaged across its replicates, and 
the treated and untreated strains were compared to calculate residual growth. 
Positive strains were identified with residual growth of less than 80% and p-value 
of less than 0.05. For validation studies, we grew selected strains from the 
screening experiment and completed the rest of the procedure identical to the 
library screening; the only exception was the cut-off for validated positives was 
residual growth of less than 70% and p-value of less than 0.05.  
 
2.5.5 GO enrichment and analysis 
GO enrichment analysis is a categorisation step of our validated positives. 
It annotates each positives, called GO term and divided the validated positives 
into groups of common GO term based on biological proess, molecular function 
and cellular component (Ashburner et al., 2000). It asses statistical significance 
of each GO term groups by comparing the positives gained in a particular Go 
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term from study against the total number of   genes included in the study 
(background) that belonged to the GO term. Therefore, the more number of 
positives belonging to a particular GO term acquired, the more statistically 
enriched that GO term which are reflected upon their corresponding p-values. 
Such analysis tool is available on Yeastmine (Balakrishnan et al., 2012). I 
uploaded our positives on Yeastmine but the analysis of the homozygous 
deletion library and DAmP library of each bee product treatment is done 
separately because of different yeast backgrounds.  
 
2. 6 Iron ion rescue 
2.6.1 Iron ion rescue broth dose response 
We prepared a custom agar plate by inoculating selected strains from the 
yeast deletion library into 96-well microtiter plate containing 200 µl SC or 
SC+HEPES in a format in which each strain has triplicate wells. We used Singer 
Rotor HDA to inoculate the yeast from the previous microtiter plate onto the YPD 
agar plate and grew the yeast for 24 hours at 30°C. We then used Singer Rotor 
HDA to inoculate the yeast from our custom agar plate into 96-well microtiter 
plate containing 200 µl. The inoculated 96-well plate was grown for 24 hours at 
30°C. Each treatment was prepared in triplicate.  
 To study the effect of iron rescue under different propolis treatment 
concentrations, we grew select strains in a particular propolis concentration 
ranging from 0% (untreated) to 1% (agar screening concentration) with or 
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without 100 µM FeCl2 supplementation. We incubated the plates for 24 hours at 
30°C and measured absorbance at OD590 using Perkin Elmer Envision Plate 
Reader. We normalised the absorbance reading by deducting the average 
absorbance reading of each triplicate wells with the average absorbance of the 
media without yeast triplicate of each plate and compared the normalised 
absorbance reading of the a strain without FeCl2 supplementation to that of the 
same strain with 100 µM FeCl2 supplementation.   
To study the effect of different iron concentrations rescuing the growth 
of yeast under propolis treatment, we repeated the same procedure as above, 
but with using a fixed concentration of 0.25% propolis treatment; this was the 
minimal concentration of propolis to completely inhibit growth of yeast even 
after 48 hours and a concentration of FeCl2 ranging from 0 µM to 100 µM. We 
also included another plate containing only SC+HEPES media as untreated 
control. For analysis, we measured the residual growth using the following 
equation: 
Residual Growth (%) = 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑡𝑟𝑎𝑖𝑛 𝑂𝐷 𝑟𝑒𝑎𝑑𝑖𝑛𝑔  𝑤𝑖𝑡ℎ 100µ𝑀 𝑖𝑟𝑜𝑛 𝑠 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑡𝑟𝑎𝑖𝑛 𝑂𝐷 𝑟𝑒𝑎𝑑𝑖𝑛𝑔 𝑠𝑜𝑙𝑣𝑒𝑛𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
× 100% 
We compared the residual growth of each strain and at each FeCl2 concentration 
to that of BY4741 strains. 
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2.6.2 Other metal ion rescue broth dose response  
We prepared 96-well microtiter containing 200µl media containing 
SC+HEPES media with 100µM copper chloride (CuCl2), 100µM manganese 
chloride (MnCl2), 100µM magnesium chloride (MgCl2), or 100µM zinc chloride 
(ZnCl2) and including another triplicate without metal ion supplementation. We 
tested the metal ion supplementation effect against propolis treatment at 0% 
(untreated), 0.06%, 0.25% and 1%. Each strains are tested against each 100µM 
metal ion supplementation and range or propolis treatment in triplicate. 
2.6.3 OPERA imaging & fluorescence quantification 
We replicated a GFP library copy from frozen GFP library copy from the -
80°C freezer onto SC-HIS with ClonNAT and Hgh. Our GFP strains possess 
mCherry RFP fluorescence for nucleus identification. Overlapped GFP and RFP 
marker signal is indicated by yellow fluorescence signal, indicating colocalisation.  
The construction of the strain is described in Bircham et al. (2011). We inoculated 
select GFP strains chosen from propolis and bee venom validation each into 5ml 
tube containing 2ml SC broth and grow the strains overnight. We inoculated 10ul 
of each strain into a separate cuvette and measured the absorbance of each 
grown strain. For each strain we prepared a stock yeast which has the 
absorbance of OD0.1 in 1 ml 1.5 ml microcentrifuge tube. We prepared a Pelkin-
Elmer 384 fluorescence plate to contain 45µl media with particular treatment 
conditions along with untreated media as comparison. We inoculated 15µl of 
each yeast stock into respective wells of the fluorescence plate. We incubated 
the plate for 7.5 hours for the cells to grow and reached sufficient number for 
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imaging and fluorescence quantification.  Both GFP and RFP images were 
acquired using OPERA confocal microscope and GFP fluorescence quantification 
was performed using OPERA-bundled Acapella software, following the 
procedure outlined by Bircham et al. (2010) but 1000 millisecond exposure time 
was applied instead. The microscopic images of the GFP and RFP were overlaid. 
 
2.7 Phosphatidylcholine (PC) quantification assay 
2.7.1 Preparation of crude cell lysate 
The phosphatidylcholine (PC) assay was done using the Abcam 
phosphatidylcholine assay kit (ab83377). We performed broth dose response as 
described in 2.4.3 with bee venom concentrations tested at 0.1 and 0.2 µl/ml 
respectively and six replicates. Following 18 hours after yeast inoculation, all six 
replicates of solvent control and two bee venom concentrations were pooled 
into 1.5ml 1.5 ml microcentrifuge tube. 10 µl of each pool was then diluted with 
990 µl sterile water in cuvettes. The absorbance was measured at 660nm and 
the reading of each diluted pool was correlated with the cell concentration to 
assess the cell concentration of each pool. The cell concentration was then 
normalised in a way that each pool had an amount of cells equal to the pool with 
the least amount of cells. All normalised pools were then centrifuged at 16000g 
for 5 minutes. The supernatant was removed from each pool. To each pool, 100 
µl of sterile glass beads along with 200 µl extraction buffer were added (0.2% v/v 
Triton, 1% SDS, 100mM NaCl, 10 mM Tris-Cl (pH9.0), 1 mM EDTA). Each pool was 
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then vortexed for 12 minutes at maximum speed. The mixture of each pool was 
removed and added to fresh 1.5 ml microcentrifuge tube.  
2.7.2 PC assay preparation 
The assay was conducted following the protocol supplied by Abcam. 
Briefly, a standard of 0,2,4,6,8 and 10 µl of diluted PC standard was prepared and 
PC assay buffer was added to bring the total volume of 50 µl in 96-well microtiter 
plate. PC reaction mix was prepared with PC assay buffer, PC Hydrolysis Enzyme, 
PC probe and PC development mix at ratio of 44:2:2:2. 50µl of each pooled 
sample was added to the 96-well microtiter plate in triplicate. 50µl of the PC 
reaction mix was added to each standard and sample well, bringing the final 
volume of 100 µl in each well. For the background controls, 50µl of background 
mix that consists of PC assay buffer, PC probe and PC development mix added at 
the ratio of 46:2:2 was added instead. The plate was shaken at 1000 rpm for 30 
seconds, wrapped with aluminium foil and incubated at room temperature for 1 
hour instead of the outlined protocol of 30 minutes. The incubated plate was 
then fed into Bio System Multiwell plate scanner and absorbance at 570 nm was 
measured for each well. The absorbance reading of each strain and treatment 
was normalised against their respective strain background absorbance readings. 
The normalised absorbance readings were then correlated with their 
corresponding PC concentration following the protocol supplied by Abcam. The 
data was then graphed and p-value was calculated for statistical significance by 
using Student t-test. 
. 
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  3.0 Results and Discussion of Propolis 
3.1 Results 
3.1.1 Methanolic fraction of propolis showed greater inhibition compared to 
crude propolis in both agar and broth media. 
The methanolic extract of propolis showed greater potency than the crude 
water-dissolved extract in both liquid media and agar media (Figure 3.1). In crude 
propolis, we observed strong inhibition at 2% v/v, whereas the methanolic extract 
showed complete inhibition at a concentration as low as 0.25% v/v. We found 
similar pattern when we performed the dose response assay in agar media in 
which inhibition was observed in 2% crude fraction propolis but we found strong 
inhibition even at concentration as low as 0.5% v/v methanolic extract. Although 
we observed that the agar media required greater concentration of propolis to 
exert potency, the methanolic fraction of bee propolis was still more inhibitory 
compared to the crude fraction. 
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Figure 3.1. (A)Residual growth of crude fraction and methanolic fraction propolis at 24th hour 
after inoculation. (B) BY4741 wildtype yeast colonies grown on 500µl SC+HEPES (SCH) agar 
media with presence of bee propolis between 0.5% - 2% v/v in 106 cells on top 104 cells on 
bottom left and 102 cells on bottom right. The colony size was taken 48 hours after inoculation. 
 
3.1.2 Chemical genetics screen indicates enrichment for iron ion transport 
To move on to screening our homozygous deletion and DAmP libraries, we 
chose to proceed with using methanolic extracts of propolis because it was more 
potent than crude extract. To optimise the concentration for chemical genetic 
screening, we performed agar dose response of a plate from our deletion library 
collection in 1536-colonies array format. We performed the dose response assay 
at concentration between 0.5–2% v/v. Using ScreenMill, we picked the 
concentration of screening based on the median growth ratio of our his3∆ border 
control strains (Figure 3.2). The his3∆ strain were used to assess growth inhibition 
as our homozygous deletion library strains all has HIS3 gene deleted (refer section 
2.1). We chose 1% v/v because the growth ratio was in the range of 1.10 to 1.20, 
which indicates 10-20% reduction in growth of yeast under propolis treatment, 
and also the fact that the growth ratio is similar to that at 1.5% and 2%. This 10-
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20% growth defect leaves an 80-90% window open to detect additional growth 
defect due to genetic mutations in the deletion and DAmP libraries.  
 
Figure 3.2. his3∆ border strains were used for selecting propolis   concentration 
for screening. Above is the experimental plate at 1% v/v propolis treatment.The 
colony size was measured using Screenmill Data Review Engine (Dittmar, Reid, & 
Rothstein, 2010) 
 
From the screening of propolis against yeast haploid deletion library and the 
DAmP library, 22 out of ~4300 deletion mutant strains exhibited a significant 
growth defect, i.e., mutant strains showing growth ratio of greater than 1.2 
(Appendix Table B.1.1). We used SGD YeastMine web software to assess for 
biological process enrichment from our validated positives. From YeastMine, the 
top validated hits belong to response to chemical, followed by ion transport and 
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DNA damage response (Appendix Table A 1.1). On the other hand, 24 out of 839 
strains from the DAmP library exhibited hypersensitivity against propolis 
treatment (Appendix Table B.1.2). We utilised YeastMine to find the most 
enriched biological process affected by propolis treatment. During this process, 
we separated hits from deletion library and DAmP library and identified that metal 
ion transport was the most enriched biological process, particularly iron ion 
transport (Appendix Table A.1.1). Other than metal ion transport, propolis also 
showed enrichment for response to stress and intracellular mRNA localisation. 
The DAmP library showed enrichment for small nucleolar RNA (snoRNA) which 
snoRNA is to aid specific ribosomal RNA (rRNA) modification (Dieci, Preti, & 
Montanini, 2009). It is interesting that the top ten most enriched processes were 
all consists of RRP43, SEN1, CSL4 and PRP4 (Table A.1.2). 
 
 3.1.3 Iron supplementation rescued growth inhibition caused by propolis. 
To further investigate the target of iron metabolism, we performed a liquid 
dose response of propolis from 0.03% v/v to 1% v/v concentration under 100 µM 
FeCl2 supplementation on our wildtype and deletion mutant strains of the genes 
involved in iron-ion transport (Philpott & Protechenko, 2008). We found that iron 
supplementation rescued the growth inhibition induced by propolis across all our 
deletion strains as well as the BY4741 wildtype (Figure 3.3, Table 1). The deletion 
strains involved in plasma membrane high-affinity iron ion transport all showed 
hypersensitivity toward propolis treatment at concentration as low as 0.03% v/v 
propolis where the complete inhibition (less than 10% residual growth) was 
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observed. However, aft1∆ and aft2∆ mutants showed hypersensitivity but not 
complete inhibition. Aft1p and Aft2p are both transcriptional factors that play a 
central role in iron ion homeostasis sharing some substrate targets  (Courel, Lallet, 
Camadro, & Blaiseau, 2005; Yamaguchi-Iwai, Dancis, & Klausner, 1995; Blaiseau, 
Lesuisse, & Camadro, 2001).  
Also, strains such as fet3∆ and atx1∆ showed greater sensitivity against propolis 
even with presence of 100 µM FeCl2 compared to wildtype and other deletion 
strains (Figure 3.3A). The ferrireductase deletion mutants, fre1∆, fre2∆, fre3∆, 
fre6∆ showed different response at 0.03% v/v propolis where complete inhibition 
was achieved in fre1∆, hypersensitivity was achieved in fre6∆ and fre3∆, whilst 
fre2∆ showed inhibition similar to BY4741 wildtype. fre4∆ and fre5∆ mutant 
strains were not investigated in this study since these strains do not exist in our 
deletion library. The siderophore iron transport deletion mutant strains (arn1∆, 
arn2∆, arn3∆, arn4∆) showed hypersensitivity against propolis at 0.03% v/v with 
complete inhibition achieved in arn1∆ and arn2∆. Interestingly, the plasma 
membrane low-affinity iron (II) transport deletion mutant fet4∆  (Dix D. R., 
Bridgham, Broderius, Byersdorfer, & Eide, 1994) was not inhibited at 0.03% v/v 
propolis indicating that the low affinity iron transporter were unaffected by 
propolis treatment. The vacuolar iron transporters deletion mutant fet5∆ and 
fth1∆ showed hypersensitivity against 0.03% v/v propolis treatment both at ~40% 
residual growth but smf3∆ showed sensitivity comparable to wildtype. The FIT 
proteins deletion mutants, fit1-3∆ all showed propolis sensitivity comparable to 
wildtype. Taken together, these results indicate that iron content is essential in 
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resisting propolis-induced growth inhibition and that some but not all mechanisms 
of iron uptake is essential as yeast response against propolis treatment. 
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(H) 
 
Figure 3.3 Residual growth of select deletion strains under propolis treatment 
with or without 100 uM FeCl2 after 24 hours inoculation. (A) BY4741 wildtype 
(B) High affinity plasma membrane iron ion transport. (C) Regulators of iron ion 
transport. (D) Siderophore-bound plasma membrane iron transporters. (E) 
Siderophore-bound iron retention proteins (F) Low-affinity plasma membrane 
iron ion transport. (G) High-affinity vacuolar iron transport. (H) Low-affinity 
vacuolar iron ion transport. Error bars represents standard deviation of residual 
growth. 
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Residual Growth (%) 
0.03% 0.13% 0.50% 1% 
BY4741 65.90 1.83 2.74 1.10 
BY4741+ 100µM FeCl2 100.90 92.52 77.36 1.31 
∆ ftr1 0.41 0.96 3.22 1.88 
∆ ftr1 + 100µM FeCl2 97.22 53.81 54.49 2.94 
∆ fet3 0.18 4.98 2.83 2.61 
∆ fet3 + 100µM FeCl2 89.53 53.10 55.40 3.67 
∆ ccc2 1.51 1.26 0.63 1.22 
∆ccc2 + 100µM FeCl2 92.06 75.12 66.06 8.59 
∆atx1 5.14 1.42 12.52 2.40 
∆atx1 + 100µM FeCl2 70.11 35.40 19.49 5.56 
∆ fre1 11.39 2.14 4.28 4.16 
∆fre1 + 100µM FeCl2 106.00 83.49 78.10 1.16 
fre2∆ 89.83 2.77 2.87 2.63 
∆fre2 + 100µM FeCl2 99.18 95.19 81.52 21.86 
∆ fre3 53.82 2.30 1.75 1.25 
∆fre3 + 100µM FeCl2 101.37 91.14 77.08 5.53 
∆aft2 34.37 2.41 3.87 2.17 
∆aft2 + 100µM FeCl2 98.28 95.86 82.81 9.46 
∆ aft1 26.13 1.16 6.88 1.46 
∆aft1 + 100µM FeCl2 91.34 84.26 86.82 0.54 
∆ arn1 3.76 1.81 2.58 1.67 
∆arn1 + 100µM FeCl2 101.56 94.72 84.01 4.43 
∆arn2 1.08 0.84 0.42 1.79 
∆arn2 + 100µM FeCl2 95.13 77.45 88.17 5.52 
∆arn3 32.33 1.58 3.26 1.63 
∆arn3 + 100µM FeCl2 99.75 91.58 84.29 7.63 
∆arn4 29.20 3.79 1.56 0.80 
∆arn4 + 100µM FeCl2 101.16 97.43 79.11 6.29 
fit1∆ 44.04 1.82 2.71 1.50 
∆fit1 + 100µM FeCl2 96.16 93.14 83.84 7.30 
∆fit2 74.51 1.26 3.81 2.41 
∆fit2 + 100µM FeCl2 99.95 95.90 81.64 18.01 
∆fit3 57.56 1.25 1.15 1.82 
∆fit3 + 100µM FeCl2 98.86 94.58 73.98 5.67 
∆fet4 103.02 3.60 12.31 3.83 
∆fet4 + 100µM FeCl2 96.86 94.30 81.32 33.22 
∆fet5 28.50 1.09 0.76 0.52 
∆fet5 + 100µM FeCl2 98.13 95.43 73.28 7.02 
∆fre6 18.99 1.51 2.19 1.90 
∆fre6 + 100µM FeCl2 102.33 99.58 88.39 14.04 
∆fth1 36.23 1.83 0.77 0.72 
∆fth1 + 100µM FeCl2 98.96 94.66 80.81 3.76 
∆smf3 56.18 3.14 4.52 2.57 
∆smf3 + 100µM FeCl2 97.31 95.17 85.77 8.61 
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Table 1. Tabulated residual growth of  select deletion strains with or without 100 
uM FeCl2 after 24 hours inoculation. 
3.1.4 Other metal ions supplementation indicates different growth rescue 
patterns 
It is noteworthy that the high-affinity iron transporter also utilises copper ions 
to carry out the iron uptake (Askwith & Kaplan, 1998). Thus, it might be possible 
that copper ions supplementation also rescues propolis-induced growth defects 
similar to ion. We were also curious as to whether other metal ions would have 
any effect as well.  The reason being propolis is rich in flavonoids and flavonoids 
were demonstrated to have metal ion chelation activity (Kandaswami & E. 
Middleton, 1997).  To test this, we conducted a growth assay on BY4741, ∆fre1, 
∆atx1, ∆ftr1, ∆fet3, ∆ccc2, ∆aft1, ∆arn1, ∆arn2, ∆arn3 and ∆arn4 mutant strains 
with 0.03% v/v methanolic fraction propolis and 100µM of CuCl2, MnCl2, MgCl2, 
CaCl2, or ZnCl2 (Figure 3.4). The BY4741 wildtype indicated that iron restored 
growth, whereas zinc was significantly lower compared to that of no metal ion 
supplementation media. Zinc ion supplementation media did not show a 
significant difference compared to no metal ion supplementation media for fet3∆, 
but we observed complete inhibition by propolis under zinc ion supplementation 
media.  
The other metal ions showed no significant differences compared to no metal 
ion media in terms of residual growth in BY4741 wildtype. However, the high-
affinity iron ion transport strains exhibited less than 10% residual growth under 
no metal ion supplementation media with the exception of ∆aft1. Also, these high-
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affinity iron ion transport strains showed specific growth rescue patterns on each 
metal ions supplementation. ∆aft1 exhibited some growth rescue effect under 
propolis treatment in media containing zinc, magnesium and manganese ions. 
∆fet3 showed significant growth rescue effect for all metal ion supplementations 
except for zinc ion. ∆atx1 exhibited growth rescue with only copper and iron ion 
supplementation. ∆ccc2 also showed similar growth rescue with copper ion 
supplementation but it is also observed that there is a slight but significant growth 
rescue with magnesium ion supplementation as well. ∆fre1 showed significant 
growth rescue effect with all but calcium ion and zinc ion supplementation. ∆atx1, 
∆ccc2, and ∆fre1 shared a similar noteworthy pattern in which copper ion 
supplementation rescued growth inhibition better than iron ion supplementation. 
In contrast, some other strains such as ∆fet3 and ∆ftr1 had MgCl2 supplementation 
rescue growth better than CuCl2 although the rescue is less than FeCl2 
supplementation. No metal ions were found to rescue ∆arn1 and ∆arn2 inhibition 
by propolis except for iron. Overall, all strains shared similar pattern to that of 
BY4741 wildtype in which FeCl2 supplementation restored the growth phenotype 
while ZnCl2 exacerbated the growth inhibition. 
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(B) 
 
 
 
Figure 3.4 Residual growth of BY4741 wildtype, under 0.03% v/v methanolic fraction propolis 
and various metal ion supplementation (Student’s t-test *P < 0.05; **P < 0.01; ***P < 0.001). 
Metal ions are supplemented as follows: calcium (100 µM CaCl2), copper (100 µM CuCl2), iron 
(100 µM FeCl2), magnesium (100 µM MgCl2), manganese (100 µM MnCl2), zinc (100 µM ZnCl2). 
Error bars represent standard deviation of averaged residual growth. 
*
0
20
40
60
80
100
120
140
No metal Calcium Copper Iron Magnesium Manganase Zinc
R
es
id
u
al
 G
ro
w
th
 (
%
)
arn1∆
*
0
20
40
60
80
100
120
No metal Calcium Copper Iron Magnesium Manganase Zinc
R
es
id
u
al
 g
ro
w
th
 (
%
)
arn2∆
57 
 
3.1.5 GFP Intensity and localisation analysis indicates upregulation of high-
affinity iron ion transporters’ GFP fluorescence 
Given my observation that iron supplementation rescued propolis-induced 
inhibition whereas zinc supplementation exacerbated the condition, I would like 
to know how propolis with or without iron or zinc could affect the expression and 
localisation of high-affinity and low-affinity iron transport proteins. To investigate 
this question, we evaluated GFP localization and intensity in the following strains 
under propolis treatment with iron or zinc supplementation: Fet3p-GFP, Aft1p-
GFP, Atx1p-GFP, Ccc2p-GFP and Ftr1p-GFP which are the high affinity iron ion 
transport proteins; Arn1p-GFP, Arn2p-GFP, and Arn3p-GFP which are the 
siderophore-bound iron ion transport proteins; Fet4p-GFP which is the low-
affinity plasma membrane iron ion transport; Fet5p-GFP, Fth1p-GFP and Fre6p-
GFP which are the high affinity vacuolar iron transport; and Smf3p-GFP which is 
involved in vacuolar low-affinity iron ion transport. Plasma membrane 
ferrireductases Fre1-3p-GFP, plasma membrane siderophore transporter Arn4p-
GFP and iron capturing complex Fit1-3p-GFP were not included in this study 
because these strains were not included in our yeast GFP library.  
Using Acapella software, I found that GFP strains of high-affinity plasma 
membrane and vacuolar iron transporters exhibited significant differences 
compared to its solvent control with exception of Aft1p-GFP. These strains 
showed an increase in GFP fluorescence intensity upon propolis treatment and 
propolis treatment with zinc supplementation although the propolis and propolis 
with zinc supplementation had comparable levels of intensity indicating 
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upregulation of these proteins (Figure 3.5). In these strains, iron supplementation 
in propolis-treated media showed GFP intensity comparable to the solvent control.  
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Figure 3.5 GFP intensity values of yeast-GFP strains (Student’s t-test *P < 0.05; **P < 0.01; 
***P < 0.001). (A) Regulator of iron ion transport  (B) High affinity extracellular iron ion 
transport. (C) Siderophore-bound iron ion transporters. (D) Low affinity extracellular iron ion 
transport. (E) Vacuolar iron ion transport.  
 
The high-affinity plasma membrane iron transporter GFP strains, Fet3p-GFP, 
Atx1p-GFP and Ccc2p-GFP showed higher intensity upon propolis treatment and 
propolis treatment with zinc supplementation compared to without propolis 
treatment (Figure 3.5A). Also, iron supplementation was found to reduce the level 
of GFP intensity back to untreated levels. In contrast, zinc supplementation to the 
media along with propolis treatment showed GFP intensity similar to the propolis 
only treatment for Fet3p-GFP, Atx1p-GFP and Ccc2p-GFP. Interestingly, Fet3p-GFP 
showed significant increase in GFP intensity under media with 100 µM ZnCl2. This 
was not observed in other high-affinity iron transport GFP strains. Atx1p-GFP 
showed a change in localisation where the fluorescence was lost from the vacuole 
in the propolis-treated media and propolis-treated media with zinc 
supplementation compared to cytoplasmic localization in control media (Figure 
3.5A). Morever, we found some localisation of Atx1p in nucleus as well under 
propolis, propolis with iron supplementation and propolis with zinc 
supplementation treatment as observed by yellow fluorescence indicating RFP 
and GFP marker signal overlap. Ccc2p-GFP showed the same punctate 
fluorescence across all treatment conditions with greater GFP fluorescence in 
propolis-treated and propolis with zinc supplementation media (Figure 3.5A). On 
the other hand, Aft1p-GFP and Ftr1p-GFP showed no significant GFP-intensity 
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changes nor localization changes across all treatment conditions compared to 
their respective solvent control (Figure 3.5A). We observed abnormalities of 
Ftr1p-GFP fluorescence but we have confirmed that the Ftr1p-GFP of our 
collection exhibited such behaviour after repeated tests.    
For the siderophore iron transporters, Arn1p-GFP, Arn2p-GFP and Arn3p-GFP 
did not show any significant difference in GFP-intensity or localization across all 
treatment conditions (Figure 3.5B). These results indicate that the propolis 
treatment did not affect the expression or activity of the Arn proteins. Similarly 
for the low-affinity iron transporter Fet4p-GFP strain, we did not observe any 
change in GFP intensity or localisation of GFP fluorescence across all treatment 
conditions (Figure 3.5C).  
The vacuolar high-affinity iron transporters GFP strains Fet5p-GFP and Fth1p-
GFP showed a significant increase in GFP fluorescence in propolis-treated and 
propolis with zinc supplementation media (Figure 3.5D). However, we did not 
observe localisation changes across all treated media for Fet5p-GFP and Fth1p-
GFP. The vacuolar ferrireductase Fre6p-GFP and low-affinity vacuolar iron 
transporter did not exhibit any change in GFP intensity or localisation across all 
treatments (Figure 3.5E).  
Based on the results from the yeast-GFP intensity and localisation analysis, 
propolis caused an increase in extracellular and vacuolar high-affinity iron 
transport GFP intensity, indicating an increase in these proteins’ expression levels 
under propolis treatment. In contrast, none of the low-affinity iron transport 
proteins showed any changes in GFP expression. Moreover, certain transporter 
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GFP strains also showed changes in localisation though not all high-affinity iron 
transport strains share that characteristic. Though we saw a significant increase in 
GFP intensity in Fet3p-GFP strain under the media with zinc supplementation but 
without propolis treatment, this pattern was not observed in all other strains. 
Moreover, for strains that showed significant increase of its GFP intensity under 
propolis treatment or propolis treatment with zinc supplementation, the intensity 
levels were not significantly different. Thus, the effect of zinc in respect to 
exacerbating the propolis-induced growth inhibition may not occur by zinc ions 
augmenting the bioactivity of propolis. 
 
 3.2 Discussion 
 
We have performed liquid dose response and agar dose response in the 
water soluble fraction and methanolic fraction of propolis and found that the 
methanolic fraction is more potent in inhibiting yeast growth. We performed 
screening of propolis against our deletion library collection and DAmP library 
collection at 1% v/v and validated the results by performing dilution assay in 
agar media. Our validated positives showed enrichment for iron ion transport. 
To further investigate which iron ion transport is being affected by propolis 
treatment and determine whether the amount of iron in media could affect the 
propolis biological activity, we challenged deletion strains involved in iron ion 
transport with 0.06% v/v propolis with or without presence of high level of iron 
100µM. We found that hypersensitivity is observed within the high-affinity iron 
ion transport with the exception of ∆aft1 that showed strong inhibition at 
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0.03% v/v propolis. Also, it was observed that iron supplementation rescued 
growth inhibition by propolis even beyond the MIC. We also determined if 
other metals could provide similar phenotypic rescue. This is to confirm 
whether the propolis activity reduce free iron ion levels specifically or it reduces 
all metal ions availability as well. Each deletion strain showed specific 
phenotypic rescue patterns in which some strains had particular metal ions that 
rescued growth inhibition at varying degrees. Intriguingly, zinc ions were found 
to increase the inhibition by propolis.  
Next, we investigated whether propolis might affect the expression and 
localisation of the iron transport proteins. We found a significant increase in 
GFP intensity for Fet3p-GFP, Atx1p-GFP and Ccc2p-GFP under propolis 
treatment and the iron supplementation brings the GFP intensity back to the 
solvent control’s level. Furthermore, propolis-treated with zinc 
supplementation condition also displayed higher GFP intensity at similar level 
to propolis-treated condition. There was also a change in localisation observed 
in Atx1p-GFP where the strains under propolis-treated and propolis-treated 
with zinc conditions showed no GFP fluorescence in vacuole. We speculated 
that Atx1p are released from vacuole to accommodate iron transport efficiency 
in response to propolis treatment. Taken together, these results suggest that 
propolis selectively stimulates the high-affinity iron transport proteins. 
Alternatively, propolis may remove iron from yeast cells and upregulate the 
high-affinity iron transporter proteins in response of iron deprivation inside 
yeast. No upregulation of Arn1p and Arn2p expression (Figure 3.5B) suggests 
that the siderophore iron transporters were not vital in low iron deprivation 
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response and that the high-affinity iron transporter being the primary means 
of iron uptake in yeast.  
In yeast, there are three mechanisms for the uptake and vacuolar transport 
of iron (Figure 3.6). The first is the high affinity iron transport that is primarily  
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Figure 3.6  Propolis chelates iron and induces iron deprivation. (A) Iron transport process under 
normal iron conditions. (B) Upregulation of both extracellular and vacuolar high-affinity iron 
transporters following propolis treatment 
 
carried out by Ftr1p through the activity of Fet3p, Atx1p and Ccc2p. This iron 
uptake process begins with the activity of ferrireductase Fre1p that reduces 
siderophore-bound iron and also cupric copper. The activity of Fre1-3p removes 
siderophore, releasing free ferrous ions (Figure 3.6A). The Fet3p-Ftr1p complex 
oxidises the low-affinity ferrous ions to high-affinity ferric ions that are then 
transported into the cells via the Ftr1p subunit (Askwith & Kaplan, 1998; 
Stearman et al., 1996; Yun et al., 2001). The second pathway is involved in low-
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affinity ferrous iron uptake which is mediated by Fet4p and SMF family proteins 
and their expression was found to be inversely related with high-affinity iron 
transport (Dix D. et al., 1997; Hassett et al., 2000). The third pathway of iron 
uptake is via Arn1-4p siderophore transporters in which these transporters 
specifically recognise siderophore for uptake into cells (Heymann et al., 2000; 
Yun et al., 2001).  
 
Our results suggest that propolis acts as a metal ion chelator, particularly 
iron, and it removes iron ion availability from yeast (Figure 3.6B). 
Hypersensitivity of high-affinity iron ion transport deletion strains against 
propolis treatment indicates that these proteins are essential in providing 
response against iron deficient conditions. This is further evident from the 
fluorescence analysis of our GFP-tagged high-affinity iron ion transport proteins 
in which all transport proteins were increased in abundance upon propolis 
treatment. Therefore, under propolis treatment, I propose that propolis 
quenches the iron available from the yeast environment and in response there 
is an increase in high-affinity iron ion transport to maximise the uptake of iron. 
This model is further supported by my observation that a high iron environment 
is created when iron is added to growth media. The iron sequestration ability 
of propolis present within the media could not completely remove iron from 
the yeast media. This is further supported with the liquid dose response of 
yeast against propolis treatment under optimal iron supplementation when the 
propolis concentration is increased up until to 1% v/v (agar screening 
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concentration) causing complete inhibition of growth. In this case, 1% v/v 
propolis was sufficient to completely remove 100µM iron ions from the media, 
creating iron-deficinent environment. It is noteworthy however, that Aft1p, 
which plays a role in positive regulation of iron ion transport, did not show any 
significant change in expression.   
 However, as observed in our metal ion rescue experiment, certain 
deletion strains as well as wildtype exhibit partial growth rescue phenotype 
under supplementation of ions other than iron or copper (Figure 3.4). A 
possible reason for this could be attributed to two factors; the non-high affinity 
iron ion transporter are non-specific in its metal ion transport capabilities (Li & 
Kaplan, 1998) and also that natural products such as  flavonoids express metal 
ion chelating activities specific to each metal ion (Mladenka et al., 2011; Flora 
& Pachauri, 2010) . In both vacuolar and extracellular environment, the non-
iron metal ion supplementation outcompetes iron from being chelated by 
flavonoids, minimising the iron deprivation effect that potentially causes 
growth inhibition in yeast. Moreover, in the vacuolar environment, the high-
affinity iron transporters are upregulated in response to propolis treatment, 
which maximises iron uptake as well as the uptake of other metal ions. This 
increase of non-iron ions would competitively minimise iron chelation. In 
contrast, for the non-high affinity iron ion transporters deletion mutants 
(Figure 3.4), only iron successfully rescued growth which suggests that the high-
affinity iron transporters are highly specific in its activities. The high-affinity iron 
ion transport mutants thus result in a failure of circumventing iron deprivation 
by propolis. It is plausible that the variable growth rescue effects in these 
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mutants possibly correlates with the efficiency of that particular metal ion as 
electron donor to take over iron function upon propolis treatment.  
Based on SGD (http://yeastgenome.org), I found only Aft1 belong under GO 
term for positive regulation iron ion transport.  This suggests that there are 
other regulators of iron ion transport, such as Aft2 that might be involved in 
upregulating the transporter proteins that belong to another GO term, cellular 
iron ion homeostasis. However, the role of proteins within the context of 
cellular iron ion homeostasis was not explored in this study.   
Metal ion chelating activity is a common factor for flavonoids although 
flavonoids display different degrees of effectiveness  (Mladenka, et al., 2011; 
Kandaswami & E. Middleton, 1997). Heavy metal ions are able to prolong the 
production of reactive oxygen species and free radicals (Prousek, 2007), thus it 
is plausible that the chelating activity of flavonoids within propolis protects cells 
from mitochondrial damage. In the case of propolis, focusing only on iron, the 
propolis chelates iron, reducing the iron availability inside or outside yeast, 
creating a low iron condition. Yeast in turn, upregulates both extracellular and 
vacuolar high-affinity iron transport specifically to maximise iron content within 
yeast. As we did not observe any change of expression of ARN1-3p siderophore 
transporter and Fet4p low-affinity iron transporter, I predict that both low 
affinity iron transporters and siderophore iron transpoters are not involved in 
yeast response to iron deprivation by propolis. 
 Different studies were carried out in analysing biological components of 
propolis isolated from different geographic locations. It was found that propolis 
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of different countries has different flavonoid compositions even within the 
geographical region of a country (Santos et al., 2002; Shiva et al., 2007; Uzel et 
al., 2005; Ahn et al., 2004). One study explored the activity of Brazilian propolis 
by employing a similar genome-wide screening approach similar to that used 
here in my thesis (Castro et al., 2011). This group demonstrated that propolis 
induced yeast apoptosis via the release of cytochrome c into cytoplasm and 
also has demonstrated an increase in reactive oxygen species (ROS). This group 
finding would seem to be in conflict with our findings in regard to propolis 
because our findings would imply propolis would cause reduction of ROS due 
to its iron chelation which in turn would reduce ROS production. However, 
another group had demonstrated that under iron deprivation, apoptosis was 
induced by the release of cytochrome c in cytoplasm and also increased ROS 
levels (Koc et al., 2005).  Therefore, we propose that the iron chelating activity 
of propolis could potentially protect yeast cells from damage by inducing 
apoptosis. Our findings added a new but congruent explanation on how the 
biological process of yeast cells were affected by propolis. However, we did not 
explore the correlation between propolis with ROS levels and also markers for 
apoptosis in this study to confirm whether there was apoptosis in our propolis 
studies as previously described by (Castro et al., 2011).   
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4.0 Results and discussion of bee venom 
4.1 Results 
4.1.1 Bee venom did not show bioactivity in agar media. 
We performed liquid dose response of BY4741 in SC+HEPES broth and agar 
dose response in SC+HEPES agar. We determined the ideal inhibition for our 
library screening at concentration of 0.2 µl/ml (Figure 4.1A), where the residual 
growth was between 80%-90% (=10-20% growth inhibition) in broth. On the other 
hand, we found that bee venom did not exhibit bioactivity in agar (Figure 4.1B). 
However, when we scaled the experiment against our deletion library, we found 
that our bee venom concentration was too strong during our first screening 
against the first 304 deletion strains in which we obtained more than 50% hits with 
significant growth defects. Therefore, we performed a liquid dose response of bee 
venom against our first 76 deletion strains (equivalent to 1 96-well plate excluding 
our his3∆ border strains) and picked the best concentration that resulted in 
approximately 10 hits. From the study, we selected 0.1 µl/ml bee venom that 
resulted in 10 hypersensitive strains per 96-well plate, an amount feasible for our 
genome-wide analysis (figure 4.1).  
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(A) 
 
  (B) 
 
 
Figure 4.1(A). Residual growth response of BY4741 against bee venom treatment under broth 
SCH media at mid-log (16th hour).(B) Bee venom dose response under agar SCH media. 
 
4.1.2 Bee venom screen indicates sensitivity in PC metabolism process 
From our primary screen of ~4300 gene deletion strains and 837 DAmP 
strains, we found 108 gene deletion strains and 47 Damp strains that had 
statistically significant growth defects based on a Student’s t-test (P < 0.05) and 
residual growth < 70%. Of these, the growth defect was reproduced in 54 deletion 
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strains (Table B.2.1) and 8 DAmP strains (Table B.2.2) in an independent analysis. 
To acquire information of the possible biological process enrichment, I submitted 
these 54 genes to YeastMine and identified that histone H3-K79 methylation, 
global genome nucleotide-excision repair and nucleotide-excision repair were the 
top three most enriched biological processes (Table A.2.1). Due to the time 
constraints of this thesis, I chose to explore the biological process belonging to the 
most sensitive gene deletion mutant, which is ∆srf1 (Table B.2.1). ∆srf1, ∆psd2, 
∆pct1, ∆ept1, ∆opi3, ∆cki1, ∆cpt1, ∆psd1, ∆spo14, ∆isc1 and ∆lro1 which involves 
either in PC anabolism or catabolism (Ejsing et al., 2009). ∆cds1, ∆cho1 and ∆ect1 
were also involved in PC biosynthesis but they were not included because they 
were absent from our deletion library collection. We performed a broth growth 
assay of these mutant strains with 0.1 µl/ml and 0.2 µl/ml bee venom. The 0.1 
µl/ml was performed as it has the same concentration as performed during 
screening as explained in 4.1.1 whereas 0.2 µl/ml was the ideal concentration 
which we observed ~85% residu4.al growth (i.e. ~15% growth inhibiton) in the 
broth dose response studies (Figure 4.1A). As explained in 3.1, 0.2 µl/ml bee 
venom gives the ideal concentration for screening but we had too many hits at 
that particular concentration that we reduce the screening concentration to 0.1 
µl/ml. Thus, by increasing the bee venom concentration to 0.2 µl/ml, we could 
discover more mutant strains that hypersensitive to bee venom treatment that 
would not be discovered when the dosage of bee venom was 0.1 µl/ml. We indeed 
found fewer hits on 0.1µl/ml where only ∆pct1 and ∆srf1 was hypersensitive at 
BY4741 wildtype mid-log phase (16th hour) and only ∆cpt1 was hypersensitive at 
BY4741 wildtype stationary phase (24th hour) (Figure 4.2). On the other hand, we 
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found ∆pct1 ∆cki1, and ∆cpt1 to be hypersensitive at mid-log phase and ∆eki1, 
∆pct1, ∆ept1, ∆cki1, and ∆cpt1 were hypersensitive at stationary phase. BY4741 
was found to show significant difference of 87% residual growth (13% growth 
inhibition) at mid-log phase which is coherent with our previous broth dose 
response assay (Figure 4.1A). ∆psd1 appeared to be growth stimulating under bee 
venom treatment but the difference was not statistically significant. We had to 
omit ∆opi3, ∆isc1, and ∆lro1 because they exhibit slow growth that infeasible for 
broth dose response experiment. The incongruent hypersensitive hits at BY4741 
wildtype mid-log phase and BY4741 wildtype stationary phase is likely due to 
difference of growth rate across all mutant strains that either their mid-log phase 
comes later than the BY4741 wildtype that their hypersensitivity is observed at 
24th hour but not at 16th hour or that their mid-log phase comes earlier than 
BY4741 wildtype that their hypersensitivity is observed at 16th hour but not at 24th 
hour. All these mutant strains hits could be categorised in three particularly 
pathways relating to PC metabolism. One group consists of Eki1 and Ept1 which 
utilises ethanolamine to make PE, another group consists of Cki1, Pct1, Cpt1 and 
Ept1 that utilises choline to make PE and the final group consists of Spo14 and Srf1 
that breaks down PC to PA and choline (Birner et al., 2001; Ejsing et al., 2009; 
Kennedy et al., 2011) .These results suggests that the bee venom may inhibit 
specific proteins within the PC metabolic processes (Figure 4.5).  
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Figure 4.2.(A)  Residual growth of deletion strains involved in phosphatidylcholine metabolism 
under 0.1 µl/ml bee venom treatment at BY4741 wildtype mid-log phase (16th hour) and 
stationary phase (24th hour) . (B) Residual growth under 0.2 µl/ml bee venom treatment at 
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BY4741 wildtype mid-log phase (16th hour) and stationary phase (24th hour). (Student’s t-test 
*P < 0.05; **P < 0.01; ***P < 0.001) 
 
4.1.3 GFP intensity and localisation studies showed suppression of Opi3p-GFP 
fluorescence 
To study the effect of bee venom on the proteins in PC metabolism, I 
measured the expression levels of proteins involved in glycerol biosynthesis 
metabolism and PC metabolism as from Ejsing et al. (2009), in response to 0.1 
µl/ml or 0.2 µl/ml bee venom. Specifically I examined Spo14p-GFP, Cki1p-GFP, 
Eki1p-GFP, PCt1p-GFP, Cho2p-GFP, Psd1p-GFP, Cpt1p-GFP, Ept1p-GFP and Opi3p 
GFP, strains similar to 4.1.2. Srf1p-GFP, Isc1p-GFP, Psd2p-GFP and lro1p-GFP were 
not included in this study for these strains were not available in the yeast GFP 
library.  
We did not observe any significant changes in GFP intensity or localisation 
of Cho2p-GFP, Psd1p-GFP, Spo14p-GFP, Cki1p-GFP, Eki1p-GFP, PCt1p-GFP, Cpt1p-
GFP, or Ept1p-GFP. Only Opi3p-GFP showed a significant decrease in GFP intensity 
under bee venom treatment and this was not associated with a change in 
localisation (Figure 4.3).  
 
 
87 
 
 
 
 
                                             
   Solvent control 
                                              
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
 
0.2 µl/ml bee 
venom 
*
*
0
100
200
300
400
500
600
Solvent control 0.1 µl/ml 0.2 µl/ml
G
F
P
 I
n
te
n
si
ty
Opi3p-GFP
88 
 
 
0
10
20
30
40
50
60
70
80
Solvent control 0.1 µl/ml 0.2 µl/ml
G
FP
 In
te
n
si
ty
Eki1p-GFP
Solvent control 
0.1 µl/ml bee venom 
0.2 µl/ml bee venom 
89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             
Solvent control 
                                              
 
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
 
0.2 µl/ml bee 
venom 
0
20
40
60
80
100
120
140
Solvent control 0.1 µl/ml 0.2 µl/ml
G
FP
 In
te
n
si
ty
Cki1p-GFP
90 
 
 
 
 
                                             
Solvent control 
                                              
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
0.2 µl/ml bee 
venom 
0
10
20
30
40
50
60
70
80
90
Solvent control 0.1 µl/ml 0.2 µl/ml
G
FP
 In
te
n
si
ty
Pct1p-GFP
91 
 
 
 
 
                                             
Solvent control 
                                              
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
0.2 µl/ml bee 
venom 
0
10
20
30
40
50
60
70
80
90
100
Solvent control 0.1 µl/ml 0.2 µl/ml
G
FP
 In
te
n
si
ty
Cpt1p-GFP
92 
 
 
 
 
                                             
Solvent control 
                                              
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
 
0.2 µl/ml bee 
venom 
0
20
40
60
80
100
120
Solvent control 0.1 µl/ml 0.2 µl/ml
G
FP
 In
te
n
si
ty
Ept1p-GFP
93 
 
 
 
 
                                             
   Solvent control 
                                              
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
 
0.2 µl/ml bee 
venom 
0
10
20
30
40
50
60
70
80
90
100
Solvent control 0.1 µl/ml 0.2 µl/ml
G
FP
 In
te
n
si
ty
Psd1p-GFP
94 
 
 
 
 
                                             
   Solvent control 
                                              
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
 
0.2 µl/ml bee 
venom 
0
50
100
150
200
250
Solvent control 0.1 µl/ml 0.2 µl/ml
G
FP
 In
te
n
si
ty
Cho2p-GFP
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             
   Solvent control 
                                              
 
 
0.1 µl/ml bee 
venom 
                                          
 
 
 
 
0.2 µl/ml bee 
venom 
0
10
20
30
40
50
60
70
80
90
Solvent control 0.1 0.2
G
FP
 In
te
n
si
ty
Spo14p-GFP
96 
 
Figure 4.3 GFP intensity measurement of GFP-tagged proteins involved and their 
respective fluorescence localisation (Student’s t-test *P < 0.05). Red fluorescence 
indicates nucleus location. 
 
It is noteworthy that at 0.2 µl/ml bee venom treatment, the cells appear to 
be smaller and for the non-nuclear localised yeast GFP strains, the RFP 
fluorescence overlaps with the GFP fluorescence which the RFP signal is found in 
cytoplasm(e.g. Opi3p-GFP in Figure 4.3). This suggests that nucleolar proteins are 
now found outside nucleus implicating that the membrane integrity of yeast is 
compromised.  These results suggest that bee venom may affect yeast’s 
physiology by selectively inhibiting Opi3p expression and this Opi3p 
downregulation effect might explain the leak of RFP signal observed at 0.2 µl/ml. 
 
4.1.4 PC quantification assay indicates PC decline with bee venom treatment 
To directly measure the effect of bee venom on PC metabolism, I 
quantified PC in BY4741 wildtype, ∆srf1 and ∆spo14 with two concentrations of 
bee venom, 0.1 µl/ml and 0.2 µl/ml. ∆spo14 was also included for we would like 
to observe the effect bee venom on PC metabolism under absence of PC 
breakdown mechanism. BY4741 and ∆srf1 showed a significant decrease of PC 
under 0.1 µl/ml and 0.2 µl/ml bee venom treatment (Figure 4.4). However, 
spo14∆ showed no significant difference under 0.1 µl/ml bee venom treatment 
but a significant decrease of PC concentration was observed under 0.2 µl/ml bee 
venom. Interestingly, the PC phenotype of spo14∆ in 0.2 µl/ml bee venom was 
97 
 
not as dramatic as compared to srf1∆ and BY4741 wildtype. These results 
indicate that bee venom either suppresses PC synthesis or upregulates PC 
catabolism.      
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Figure 4.4. PC amount of BY4741, ∆spo14 and ∆srf1 under 2 different bee venom 
concentration. BV 0.1 and 0.2 represents 0.1 µl/ml and 0.2 µl/ml bee venom respectively. 
(Student’s t-test *P < 0.05; **P < 0.01) 
 
4.2 Discussion 
As I identified that bee venom was not bioactive in agar, possibly due to 
heat-sensitive bioactive components of bee venom (e.g. melittin) not being stable 
in molten agar when the bee venom was added to agar. Genome-wide analyses of 
bee venom were then conducted in liquid media and we determined that 108 
deletion strains were hypersensitive to bee venom and we used one of the most 
sensitive strains (srf1∆) to elucidate molecular mechanisms of bee venom in 
regulating PC metabolism.  
   There are two pathways in which PA could be converted to PC. The first 
one being the conversion to PC via PS and PE intermediates whereas the other one 
involves DAG intermediate. The DAG intermediate has two primary pathways; one 
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that produces PC directly from DAG and the other one indirectly via PE 
intermediate (Ejsing et al., 2009). Eki1p and Ept1 synthesise PE via CDP-
ethanolamine pathway (Birner, Burgermeister, Schneiter, & Daum, 2001; Ejsing, 
et al., 2009) via exogenous ethanolamine as its starting materials (Birner et al., 
2001). Cki1p, Cpt1p, Pct1p and Ept1p on the other hand, manufacture PC directly 
from exogenous choline. Ept1p is essential for both PE and PC biosynthesis to 
occur (Birner et al., 2001). In contrast, mutant strains psd1∆ and psd2∆, which 
synthesise PE from PS under the CDP-ethanolamine pathway, were not 
hypersensitive to bee venom. The Kennedy pathway for manufacturing PC via 
Cki1p becomes essential in the psd1∆ psd2∆ double mutant but not eki1∆, which 
implies that the PE-mediated Kennedy pathway for PC synthesis is insufficient to 
meet the minimum PC amount required for yeast viability. Therefore, the 
hypersensitivity observed in eki1∆, pct1∆,ept1∆ cki1∆, , and cpt1∆ (figure 4.2B) 
may be due to bee venom inhibiting proteins within the CDP-ethanolamine 
pathway, causing reduction of PE or PC. On the other hand, the hypersensitivity of 
eki1∆ may be due to the significant reduction of PE due to the defective machinery 
of PE biosynthesis from exogenous ethanolamine source coupled with inhibition 
of PE synthesis via CDP-ethanolamine pathway by bee venom.  
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Furthermore, srf1∆ but not spo14∆ was found to be hypersensitive against 
bee venom. Spo14p is phospholipase D that directly breaks down PC to PA and 
choline and Srf1p is regulator to Spo14p activity (Ejsing et al., 2009; Kennedy et al., 
2011). This suggests that unregulated Spo14p phospholipase D activity but not its 
absence is required for hypersensitivity. This is coherent with my hypothesis that 
bee venom regulates the levels of PC in yeast via inhibition of PC biosynthesis.  
Protein expression level analysis by GFP intensity indicated that only Opi3p 
levels were downregulated by bee venom treatment. Even the proteins that 
function upstream of Opi3 in CDP-ethanolamine pathway, Psd1p and Cho2p did 
not show downregulation of expression as observed in Opi3p. This suggests that 
bee venom inhibits PC anabolism by suppressing Opi3p activity that catalyses the 
last two steps of PC biosynthesis. These results abrogate the possibility of my 
earlier inference that bee venom specifically inhibits PE biosynthesis from the 
ethanolamine pathway and PC biosynthesis from the choline pathway. 
Furthermore, we did not observe any increase of Spo14p upon bee venom 
treatment which suggests that bee venom did not increase breakdown of PC. 
However, it is possible that PC is being removed by activity of Lro1p; unfortunately 
Lro1p expression under bee venom treatment was not assessed in our study. In 
summary, my GFP analyses suggest that bee venom inhibits PC biosynthesis by 
selectively suppressing Opi3p from synthesising PC. 
The results from our PC levels assay indicate that there are significant 
reduction of PC amount under bee venom treatment for BY4741 wildtype, srf1∆ 
and spo14∆. spo14∆ showed less reduction of PC under bee venom treatment 
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compared to solvent control which is consistent with the function of Spo14p, a 
phospholipase D that breaks down PC. However, the fact that PC reduction is still 
observed in spo14∆ implicates other proteins that recycle constituents of PC (e.g., 
Lro1p).    
PC is involved in membrane signalling in which it is a precursor to various 
secondary messenger molecules and thus implicating the significance of PC in cells 
to generate PC-derived messenger that results in cell growth (Wright et al., 2004). 
Previous studies demonstrated that inactivation of PC increased apoptosis and the 
cause of apoptosis linked with accumulation of the PC precursor, CDP-choline (Cui 
et al., 1996; Gasull et al., 2002; Williams et al., 1998). This is in line with our 
observation of pct1∆ being less hypersensitive to bee venom treatment compared 
to cpt1∆ and ept1∆ (Figure 4.2B) as Pct1p catalyses the reaction of choline 
phosphate and CDP to form CDP-choline (Ejsing et al., 2009). However, we did not 
found downregulation of Cpt1p and Ept1p in our yeast GFP assay, suggesting that 
the bee venom-induced cell death (via apoptosis or necrosis) is not via CDP-
accumulation. 
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Figure 4.5 Bee venom inhibits PC biosynthesis via Opi3p. PC biosynthesis and salvage network 
pathways. CDP: Choline diphosphate; DAG: Diacylglycerol; Etn: Ethanolamine; P-Etn: 
Phosphorylated ethanolamine; Cho: Choline; MMPE: monomethyl-phosphatidylethanolamine; 
DMPE: Dimethyl-phosphatidylethanolamine 
 
Together, our results indicate that bee venom induces growth inhibition by 
suppressing PC (Figure 4.6). However, Cki1p, PCt1p, Cpt1p and Ept1p that 
manufacture CDP-choline and convert it to PC were found not to be suppressed 
by bee venom (Figure 4.3). This suggests that bee venom does not induce growth 
inhibition by CDP-choline accumulation. Therefore, the bee venom might simply 
suppressing yeast growth by means of suppressing the PC-derived secondary 
messenger molecules or additional pro-survival signals other implicated in cell 
growth.  Alternatively, growth inhibition may be a consequence of deficient PC 
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levels affecting the integrity of the cell membrane. This chapter provides possible 
mechanisms to explain the previous use of bee venom as an antifungal treatment 
(Yu et al., 2012; Samy et al., 2006; Fennel et al., 1968).  
 
5.0 Bee pollen results and discussion 
5.1 Results 
5.1.1 Methanolic fraction of bee pollen showed greater inhibition compared to 
crude fraction in broth and agar media 
The methanolic fraction of bee pollen showed greater potency than the 
crude fraction in both liquid and agar media (Figure 5.1). The highest 
concentration of crude pollen (2% v/v) yielded 80% growth inhibition, while 0.25% 
v/v of the methanolic extract yielded 100% growth inhibition. In contrast, the 
crude extract of the bee pollen was not bioactive at any concentration in agar 
(Figure 5.2.). We thus determined to use 2% v/v of the methanolic extract of bee 
pollen, a concentration that inhibited growth in 1536-yeast array agar by 10% of 
his3∆ to screen the genome-wide libraries of mutant strains in agar.  
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(B) 
 
 
 
 
 
 
Figure 5.1.(A) Residual growth of crude and methanolic fraction of pollen under different 
concentrations. Residual growth was measured 16 hours after yeast inoculation. (B) Agar 
dose response of pollen in 500µl SCH + pollen. Image was taken 48 hours after yeast 
inoculation. 
 
5.1.2 Bee pollen agar screen did not show any biological process enrichment 
Of the ~4300 deletions mutant strains, only 3 deletion strains were 
validated as being significantly inhibited by bee pollen; bem1∆, swi4∆ and tef4∆ 
(Appendix Table B.3.1). From the DAmP library of 838 knockdown mutant strains, 
bee pollen treatment significantly inhibited growth of 10 strains; Yrb2-DAmP, 
Sec11-DAmP, Prp40-DamP, Sec4-DAmP, Cdc7-DAmP, Cft1-DAmP, Vrf4-DAmP, 
Rpc17-DAmP, Ctf13-DAmP, Rnt1-DAmP (Appendix Table B.3.2). Based on Gene 
Ontology (GO) enrichment analyses of these 13 genes using YeastMine, there was 
not enrichment for any process or pathway of the three deletion genes; however, 
the top three DAmP genes were enriched for the regulation of chromatin silencing 
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at telomere, regulation of chromatin silencing and regulation of gene silencing. To 
explore further categorisation, we utilised yeast GO-SLIM Mapper 
(www.yeastgenome.org) to categorise each of our positives and group them in 
broad categories. We found that 7 out of 13 genes were involved in unique 
processes, while three genes were involved in mitotic cell cycle and three 
additional genes were involved in mRNA processing (Figure 5.2).  Similar to the 
case of bee venom, we decided to explore the biological process of the mutant 
gene that was most hypersensitive to bee pollen, VRG4-DAmP. This gene is 
involved in GDP-mannose transport (Dean, Zhang, & Poster, 1997) along with 
Gda1, Psa1 and Sec53 (Caspi, 2007). 
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Figure 5.2 categorisation of all positive from bee pollen screening. The network 
was made using Cytoscape (Cline, et al., 2007) 
 
5.1.3 Broth dose response analysis of GDP-mannose biosynthesis and transport 
deletion mutant strains indicates hypersensitivity in another GDP-mannose 
transport gene 
To investigate the activity of bee pollen on GDP-mannose transport, we 
evaluated the growth of mutants impaired in GDP-mannose biosynthesis (psa1∆, 
gda1∆ and Vrg4-DAmP). Sec53 gene was not included as it was unavailable from 
our homozygous deletion and DAmP library.  At 0.125% v/v of bee pollen, we 
found that Vrg4-DAmP and gda1∆ exhibited hypersensitivity compared to BY4741 
whereas psa1∆ showed no sensitivity at all (Figure 5.3,Table 2); these results are 
in agreement with our identification of Vrg4-DAmP being hypersensitive in our 
genome-wide screen .  
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Figure 5.3. Broth dose response assay of GDP-Mannose transport deletion mutants. The 
residual growth was calculated based on absorbance (OD590) reading at 16th hour 
 
Table 2. Tabulated residual growth values of select strains under bee pollen 
treatment bee venom after 16 hour inoculation. 
 
 
 
 
Residual Growth (%) 
∆gda1 ∆psa1 Vrg4-DAmP BY4741 
0.03% Pollen 91.06 103.76 71.92 98.23 
0.125% Pollen 42.55 100.36 60.19 85.58 
0.5% Pollen 34.61 68.17 37.85 47.38 
2% Pollen 15.81 26.22 21.37 15.36 
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5.1.4 Opera image analysis of yeast GFP for GDP-mannose biosynthesis and 
transport strains indicates no changes in GFP fluorescence with bee pollen 
treatment 
To investigate the effect of pollen on the expression levels of proteins in 
the synthesis and transport of GDP-mannose, we treated Vrg4p-GFP, Gda1p-GFP, 
Sec53-GFP and Psa1p-GFP strains with two concentrations of bee pollen (0.5% 
v/v, 2% v/v). We increased the dosage of bee pollen from 0.125% v/v in the 
previous 24 hour growth analysis since the GFP assay requires a more brief 
incubation with the bee venom (5 hours). We observed no significant changes in 
GFP intensity and no observable changes in localisation in all four GFP strains 
(Figure 5.4). Vrg4p-GFP, Gda1p-GFP and Sec53p-GFP all showed punctate 
fluorescence indicative of Golgi body localisation in both solvent control and also 
the two different bee pollen concentrations (Figure 5.4A-C).  Psa1p-GFP showed 
fluorescence throughout the cells in control and pollen-treated media (Figure 
5.4D). These results suggest that the bioactivity of bee pollen was achieved by 
either targeting buffering pathways that are essential under absence of Gda1p 
or downregulation of Vrg4p or inhibiting activity of the Vrg4p without altering 
the expression level and localisation of the protein. 
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(D)  
 
 
Figure 5.4 GFP intensity measurement and localisation analysis of GDP-mannose transport 
and biosynthesis proteins indicate that there is no changes of GFP intensity and localisation. 
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5.2 Discussion 
Bee pollen showed greater bioactivity in the methanolic fraction compared 
to the crude fraction. Screening of bee pollen against both our deletion library 
collection and DAmP library collection elucidated that the bioactivity of bee pollen 
occurs via nine processes, most notably via GDP-mannose biosynthesis based on 
the Vrg4-DAmP and gda1∆ strains being sensitive to 0.125% v/v bee pollen, a 
concentration that is less than the 2% v/v concentration used in the genome-wide 
analyses.  
GDP-mannose is an essential component for cells to modify proteins and 
lipids through N-linked and O-linked glycosylation. Vrg4p essential in regard to 
GDP-mannose because Vrg4p acts as GDP-mannose transporter that brings in 
GDP-mannose from the site of synthesis at the cytoplasm into the Golgi lumen 
(Dean et al., 1997). These glycosylation steps modify proteins resulting in 
specificity in activity and stability in structure (Herscovic & Orlean, 1993), which 
are necessary to give proteins and lipids GDP-mannose is made by the precursor 
form α-D-mannose 6-phosphate that is then acted upon by Sec53p 
phosphomannomutase and Psa1p GDP-mannose pyrophosphorylase to 
synthesise GDP-α-D-mannose (Herscovic & Orlean, 1993). Golgi body acquire GDP-
mannose through the exchange of GMP as anti-porter which the latter is made 
available through the activity of Gda1p GDPase that breaks down GDP into GMP 
in Golgi lumen (Abeijon et al., 1993; Berninsone et al., 1994). Absence of Vrg4p or 
GDA1p expression were both implicated in reduction in glycosylated proteins and 
lipids (Abeijon et al., 1993; Dean et al.1997).  
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Figure 5.5 Bee pollen interferes GDP-mannose transport by blocking Vrg4p or Gda1p 
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mannose transport either via blocking the Vrg4p transporter or inhibiting the Gda1p 
enzyme from breaking down GDP to GMP.  
 
 
Our results indicate the sensitivity of the mutant strains that are necessary 
for GDP-mannose transport but not for biosynthesis. Since we identified that 
growth of Vrg4p and Gda1p mutants were sensitive to bee pollen and that this 
growth inhibition did not include changes in the localization or expression levels 
of these proteins, I propose that the bee pollen interferes with the activity of 
Vrg4p, possibly by preventing the binding of GDP-mannose or GMP to Vrg4p (GDP-
mannose transporter) or by inhibiting the binding of GDP to Gda1p (GDPase) 
(Figure 5.5). In both cases, GDP-mannose cannot be delivered effectively into Golgi 
lumen which impairs the glycosylation process. Deficiency of glycosylation would 
then lead to inviability of yeast. However, the effects of bee pollen on protein and 
lipid glycosylation were not directly examined in this study. 
 
6. Overall conclusions and future directions 
6.1 Overall conclusions 
 The aim of this thesis was to elucidate the biological pathways affected by the 
activity of propolis, bee venom and bee pollen. This thesis utilised the deletion 
library of 4,100 nonessential genes, the DAmP knockdown library of 838 essential 
genes, and select GFP strains to identify specific genes and proteins that are 
targets of these bee products.  
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 In chapter 3, propolis had shown an enrichment for iron ion transport from the 
initial primary screen of the deletion and DAmP libraries. From there on, we 
conducted follow up dose responses with various metal ion supplementation and 
also conducted GFP fluorescence analysis to elucidate genes and proteins that are 
targets of propolis in inducing iron deprivation. The iron chelating bioactivity of 
propolis was not previously reported.  
 In contrast, the results of the genome-wide analyses of bee venom bioactivity in 
chapter 4 did not show an enrichment for any biological process or pathway. I thus 
chose to further investigate the most hypersensitive strain, srf1∆. I determined 
that bee venom selectively targets Opi3p, a protein that catalyses the final two 
steps of PC biosynthesis. As PC homeostasis has not been previously reported as a 
target of bee venom, my results demonstrate that, despite lack of GO enrichment 
in the genome-wide analyses, it remains feasible to discover and characterise 
novel biological targets of a natural compound. 
 Similarly, the genome-wide analysis of bee pollen did not result in enrichment 
for any particular biological process. We instead chose one particular process 
required for normal growth in bee pollen-treated cells, GDP-mannose transport, 
for further investigation. Since we determined that normal GDP-mannose 
transport was required for normal growth in bee pollen-treated cells without any 
changes in expression levels of GDP-mannose transport proteins, we propose that 
GDP-mannose transport is a buffering mechanism targeted by bee pollen.  
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6.2 Future directions 
  There are a number of possibilities from our work on propolis, bee venom 
and bee pollen that would be useful for further investigation. In the case of 
propolis, the role of zinc in causing greater hypersensitivity to deletion mutant 
strains has not been investigated. In the case of bee venom, it would be interesting 
to investigate the possible effect of bee venom on Lro1p and other lipid 
intermediates salvaged from PC such as DAG and PA (Ejsing, et al., 2009). In the 
case of bee pollen, it is critical to further investigate the possible buffering network 
involving GDP-mannose homeostasis. In addition, there are other biological 
processes and pathways that were implicated to be affected by the bee products 
in my genome-wide analyses. Furthermore, as explained in chapter 1, different 
regions have different compositions and thus may possess different biological 
activities. We indeed observed this when our propolis showed different biological 
process enrichment compared to Castro group (2011). Also, this thesis explored 
the bee products as a mixture instead of its respective constituents. Although this 
is justified as these products are consumed as raw as it is, we could gain insights 
on which of its components attributed to its biological activities and hence 
characterise them. However, given the time constraint of my thesis, I was not able 
to further investigate these processes.  
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Appendix 
Appendix A 
Table A.1.1 Top ten most enriched GO term for biological processes from propolis homozygous 
deletion library screen 
 
GO Term P-value Gene Matches 
metal ion transport 3.06E-05 CCC2, FTR1, KHA1, FET3 
iron assimilation 3.22E-05 FTR1, FET3 
iron assimilation by reduction and transport 3.22E-05 FTR1, FET3 
arsenate ion transmembrane transport 3.22E-05 FTR1, FET3 
transition metal ion transport 4.93E-05 CCC2, FTR1, FRE1, FET3 
iron ion transport 7.38E-05 FTR1, FRE1, FET3 
iron ion homeostasis 7.45E-05 CCC2, FTR1, FRE1, FET3 
high-affinity iron ion transmembrane 
transport 
9.63E-05 FTR1, FET3 
iron ion transmembrane transport 0.000192 FTR1, FET3 
inorganic cation transmembrane transport 0.000274 CCC2, FTR1, KHA1, FET3 
 
 
 
Table A.1.2 Top ten most enriched GO term for biological processes of from propolis  DAmP library 
screen 
  
GO Term p-value Gene Matches 
snoRNA processing 0.005132 RRP43,SEN1,CSL4,PRP4 
snoRNA 3'-end processing 0.006176 RRP43,SEN1,CSL4 
snoRNA metabolic process 0.008706 RRP43,SEN1,CSL4,PRP4 
nuclear-transcribed mRNA catabolic 
process, exonucleolytic, 3'-5' 0.011091 RRP43,CSL4 
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exonucleolytic nuclear-transcribed mRNA 
catabolic process involved in 
deadenylation-dependent decay 0.011091 RRP43,CSL4 
nuclear-transcribed mRNA catabolic 
process, 3'-5' exonucleolytic nonsense-
mediated decay 0.011091 RRP43,CSL4 
nuclear-transcribed mRNA catabolic 
process, non-stop decay 0.011091 RRP43,CSL4 
ncRNA 3'-end processing 0.014956 RRP43,SEN1,CSL4 
nuclear-transcribed mRNA catabolic 
process, exonucleolytic 0.015256 RRP43,CSL4 
exonucleolytic trimming to generate 
mature 3'-end of 5.8S rRNA from 
tricistronic rRNA transcript  0.015256 RRP43,CSL4 
 
 
Table A.2.1 Top ten most enriched GO term for biological processes from bee venom yeast 
homozygous deletion library screen 
GO term p-value Gene matches 
histone H3-K79 methylation 0.001549 DOT1,RTF1 
global genome nucleotide-excision repair 0.001549 DOT1,RTF1 
nucleotide-excision repair 0.005069 DOT1,RAD23,RTF1 
regulation of DNA repair 0.006692 RTF1,SRS2 
methionine biosynthetic process 0.007406 MET8,UTR4,YLL058W 
regulation of response to DNA damage 
stimulus 0.008113 RTF1,SRS2 
sulfur amino acid biosynthetic process 0.008778 MET8,UTR4,YLL058W 
methionine metabolic process 0.011099 MET8,UTR4,YLL058W 
129 
 
snoRNA transcription from an RNA 
polymerase II promoter 0.012735 RTF1 
snoRNA transcription 0.012735 RTF1 
 
 
Appendix B 
Table B.1.1: Propolis validated hits from yeast homozygous deletion library screen  
 
Gene 
Name 
Growth 
Ratio 
Description 
MGA2 2.41 
ER membrane protein involved in regulation of OLE1 transcription; inactive ER 
form dimerizes and one subunit is then activated by ubiquitin/proteasome-
dependent processing followed by nuclear targeting; MGA2 has a paralog, 
SPT23, that arose from the whole genome duplication 
RVS161 2.24 
Amphiphysin-like lipid raft protein; interacts with Rvs167p and regulates 
polarization of the actin cytoskeleton, endocytosis, cell polarity, cell fusion and 
viability following starvation or osmotic stress 
SNF5 1.96 
Subunit of the SWI/SNF chromatin remodeling complex; involved in 
transcriptional regulation; functions interdependently in transcriptional 
activation with Snf2p and Snf6p; relocates to the cytosol under hypoxic 
conditions 
EAF1 1.94 
Component of the NuA4 histone acetyltransferase complex; acts as a platform 
for assembly of NuA4 subunits into the native complex; required for initiation of 
pre-meiotic DNA replication, likely due to its requirement for expression of IME1 
SSD1 1.89 
Translational repressor with a role in polar growth and wall integrity; regulated 
by Cbk1p phosphorylation to effect bud-specific translational control and 
localization of specific mRNAs; interacts with TOR pathway components; 
contains a functional N-terminal nuclear localization sequence and 
nucleocytoplasmic shuttling appears to be critical to Ssd1p function 
CCC2 1.88 
Cu(+2)-transporting P-type ATPase; required for export of copper from the 
cytosol into an extracytosolic compartment; similar to human proteins involved 
in Menkes and Wilsons diseases; protein abundance increases in response to 
DNA replication stress; affects TBSV model (+)RNA virus replication by 
regulating copper metabolism; human homologs ATP7A and ATP7B both 
complement yeast null mutant 
BEM1 1.77 
Protein containing SH3-domains; involved in establishing cell polarity and 
morphogenesis; functions as a scaffold protein for complexes that include 
Cdc24p, Ste5p, Ste20p, and Rsr1p 
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FTR1 1.59 
High affinity iron permease; involved in the transport of iron across the plasma 
membrane; forms complex with Fet3p; expression is regulated by iron; protein 
abundance increases in response to DNA replication stress 
YDR541C 1.49 
Aldehyde reductase; substrates are both aromatic and aliphatic aldehydes; uses 
NADPH as cofactor 
PEF1 1.46 
Penta-EF-hand protein; required for polar bud growth and cell wall abscission; 
binds calcium and zinc with different affinity; localizes to bud site in G1, bud 
neck in G2; binds to Sec31p and modulates COPII coat assembly 
SOD2 1.41 
Mitochondrial manganese superoxide dismutase; protects cells against oxygen 
toxicity; phosphorylated 
FET3 1.38 
Ferro-O2-oxidoreductase; multicopper oxidase that oxidizes ferrous (Fe2+) to 
ferric iron (Fe3+) for subsequent cellular uptake by transmembrane permease 
Ftr1p; required for high-affinity iron uptake and involved in mediating resistance 
to copper ion toxicity, belongs to class of integral membrane multicopper 
oxidases; protein abundance increases in response to DNA replication stress 
SHE4 1.38 
Protein containing a UCS (UNC-45/CRO1/SHE4) domain; binds to myosin motor 
domains to regulate myosin function; involved in endocytosis, polarization of the 
actin cytoskeleton, and asymmetric mRNA localization 
EOS1 1.37 
Protein involved in N-glycosylation; deletion mutation confers sensitivity to 
exidative stress and shows synthetic lethality with mutations in the spindle 
checkpoint genes BUB3 and MAD1; YNL080C is not an essential gene 
MAK10 1.35 
Non-catalytic subunit of N-terminal acetyltransferase of the NatC type; required 
for replication of dsRNA virus; expression is glucose-repressible 
YEL057C 1.32 
Protein of unknown function involved in telomere maintenance; target of UME6 
regulation 
FRE1 1.31 
Ferric reductase and cupric reductase; reduces siderophore-bound iron and 
oxidized copper prior to uptake by transporters; expression induced by low 
copper and iron levels 
OYE3 1.27 
Conserved NADPH oxidoreductase containing flavin mononucleotide (FMN); 
homologous to Oye2p with different ligand binding and catalytic properties; has 
potential roles in oxidative stress response and programmed cell death 
KHA1 1.25 
Putative K+/H+ antiporter; has a probable role in intracellular cation 
homeostasis; localized to Golgi vesicles and detected in highly purified 
mitochondria in high-throughput studies 
GET2 1.24 
Subunit of the GET complex; involved in insertion of proteins into the ER 
membrane; required for the retrieval of HDEL proteins from the Golgi to the ER 
in an ERD2 dependent fashion and for meiotic nuclear division 
GRR1 1.24 
F-box protein component of an SCF ubiquitin-ligase complex; modular substrate 
specificity factor which associates with core SCF (Cdc53p, Skp1p and 
Hrt1p/Rbx1p) to form the SCF(Grr1) complex; SCF(Grr1) acts as a ubiquitin-
protein ligase directing ubiquitination of substrates such as: Gic2p, Mks1p, 
Mth1p, Cln1p, Cln2p and Cln3p; involved in carbon catabolite repression, 
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glucose-dependent divalent cation transport, glucose transport, morphogenesis, 
and sulfite detoxification 
RTF1 1.17 
Subunit of RNAPII-associated chromatin remodeling Paf1 complex; regulates 
gene expression by directing cotranscriptional histone modification, influences 
transcription and chromatin structure through several independent functional 
domains; directly or indirectly regulates DNA-binding properties of Spt15p and 
relative activities of different TATA elements; involved in transcription 
elongation as demonstrated by the G-less-based run-on (GLRO) assay 
 
Table B.1.2: Propolis validated hits from yeast DAmP library screen  
 
Gene 
Name 
Growth 
Ratio 
Description 
YGL074C 2.08 
Dubious open reading frame unlikely to encode a functional protein; overlaps 5' 
end of essential HSF1 gene encoding heat shock transcription factor 
DBP9 2.03 
DEAD-box protein required for 27S rRNA processing; exhibits DNA, RNA and 
DNA/RNA helicase activities; ATPase activity shows preference for DNA over 
RNA; DNA helicase activity abolished by mutation in RNA-binding domain 
ERG13 2.01 
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase; catalyzes the formation of 
HMG-CoA from acetyl-CoA and acetoacetyl-CoA; involved in the second step in 
mevalonate biosynthesis 
GLN4 1.64 
Glutamine tRNA synthetase; monomeric class I tRNA synthetase that catalyzes 
the specific glutaminylation of tRNA(Gln); N-terminal domain proposed to be 
involved in enzyme-tRNA interactions 
ZPR1 1.64 
Essential protein with two zinc fingers; present in the nucleus of growing cells 
but relocates to the cytoplasm in starved cells via a process mediated by Cpr1p; 
binds to translation elongation factor eEF-1 (Tef1p); relative distribution to the 
nucleus increases upon DNA replication stress 
ALG13 1.6 
Catalytic component of UDP-GlcNAc transferase; required for the second step of 
dolichyl-linked oligosaccharide synthesis; anchored to the ER membrane via 
interaction with Alg14p; similar to bacterial and human glycosyltransferases; 
protein abundance increases in response to DNA replication stress 
SEC26 1.56 
Essential beta-coat protein of the COPI coatomer; involved in ER-to-Golgi 
protein trafficking and maintenance of normal ER morphology; shares 43% 
sequence identity with mammalian beta-coat protein (beta-COP) 
PRP4 1.55 Splicing factor; component of the U4/U6-U5 snRNP complex 
SEC21 1.51 
Gamma subunit of coatomer; coatomer is a heptameric protein complex that 
together with Arf1p forms the COPI coat; involved in ER to Golgi transport of 
selective cargo 
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RIB5 1.5 
Riboflavin synthase; catalyzes the last step of the riboflavin biosynthesis 
pathway 
STH1 1.5 
ATPase component of the RSC chromatin remodeling complex; required for 
expression of early meiotic genes; promotes base excision repair in chromatin; 
essential helicase-related protein homologous to Snf2p 
RRP43 1.47 
Exosome non-catalytic core component; involved in 3'-5' RNA processing and 
degradation in both the nucleus and the cytoplasm; has similarity to E. coli 
RNase PH and to human hRrp43p (OIP2, EXOSC8); protein abundance increases 
in response to DNA replication stress 
NPA3 1.45 
Member of the conserved GPN-loop GTPase family; has a role in transport of 
RNA polymerase II to the nucleus; exhibits GTP-dependent binding to PolII; has 
ATPase activity; involved in sister chromatid cohesion; phosphorylated by the 
Pcl1p-Pho85p kinase complex; human homolog XAB1 interacts with human RNA 
polymerase II; protein abundance increases in response to DNA replication 
stress 
DOP1 1.43 
Golgi-localized, leucine-zipper domain containing protein; involved in endosome 
to Golgi transport, organization of the ER, establishing cell polarity, and 
morphogenesis; detected in highly purified mitochondria in high-throughput 
studies 
SEN1 1.43 
Presumed helicase and subunit of the Nrd1 complex (Nrd1p-Nab3p-Sen1p); 
complex interacts with the exosome to mediate 3' end formation of some 
mRNAs, snRNAs, snoRNAs, and CUTs; has a separate role in coordinating DNA 
replication with transcription, by associating with moving replication forks and 
preventing errors that occur when forks encounter transcribed regions; homolog 
of Senataxin, which is implicated in Ataxia-Oculomotor Apraxia 2 and a 
dominant form of ALS 
DUT1 1.42 
deoxyuridine triphosphate diphosphatase (dUTPase); catalyzes hydrolysis of 
dUTP to dUMP and PPi, thereby preventing incorporation of uracil into DNA 
during replication; critical for the maintenance of genetic stability; also has 
diphosphatase activity on deoxyinosine triphosphate 
SPC19 1.42 
Essential subunit of the Dam1 complex (aka DASH complex); complex couples 
kinetochores to the force produced by MT depolymerization thereby aiding in 
chromosome segregation; also localized to nuclear side of spindle pole body 
UBA2 1.41 
Subunit of heterodimeric nuclear SUMO activating enzyme E1 with Aos1p; 
activates Smt3p (SUMO) before its conjugation to proteins (sumoylation), which 
may play a role in protein targeting; essential for viability 
CSL4 1.4 
Exosome non-catalytic core component; involved in 3'-5' RNA processing and 
degradation in both the nucleus and the cytoplasm; predicted to contain an S1 
RNA binding domain; has similarity to human hCsl4p (EXOSC1) 
TAO3 1.4 
Component of the RAM signaling network; is involved in regulation of Ace2p 
activity and cellular morphogenesis, interacts with protein kinase Cbk1p and also 
with Kic1p 
TRS31 1.39 Core component of transport protein particle (TRAPP) complexes I-III; TRAPP 
complexes are related multimeric guanine nucleotide-exchange factor for the 
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GTPase Ypt1p, regulating ER-Golgi traffic (TRAPPI), intra-Golgi traffic (TRAPPII), 
endosome-Golgi traffic (TRAPPII and III) and autophagy (TRAPPIII) 
YRB1 1.39 
Ran GTPase binding protein; involved in nuclear protein import and RNA export, 
ubiquitin-mediated protein degradation during the cell cycle; shuttles between 
the nucleus and cytoplasm; is essential; homolog of human RanBP1 
PSF3 1.36 
Subunit of the GINS complex (Sld5p, Psf1p, Psf2p, Psf3p); complex is localized 
to DNA replication origins and implicated in assembly of the DNA replication 
machinery 
TIF35 1.36 
eIF3g subunit of the eukaryotic translation initiation factor 3 (eIF3); subunit of 
the core complex of eIF3; is essential for translation; stimulates resumption of 
ribosomal scanning during translation reinitiation 
 
 
 
 
Table B.2.1: Bee venom validated hits from yeast homozygous deletion library  
 
Gene 
Name 
Residual 
Growth 
(%) 
Description 
SRF1 30.3 
Regulator of phospholipase D (Spo14p); interacts with Spo14p and regulates 
its catalytic activity; capable of buffering the toxicity of C16:0 platelet 
activating factor, a lipid that accumulates intraneuronally in Alzheimer's 
patients 
CYC7 34.9 
Cytochrome c isoform 2, expressed under hypoxic conditions; also known as 
iso-2-cytochrome c; electron carrier of the mitochondrial intermembrane space 
that transfers electrons from ubiquinone-cytochrome c oxidoreductase to 
cytochrome c oxidase during cellular respiration; protein abundance increases 
in response to DNA replication stress; CYC7 has a paralog, CYC1, that arose 
from the whole genome duplication 
PAU8 34.9 
Protein of unknown function; member of the seripauperin multigene family 
encoded mainly in subtelomeric regions 
MET8 39.2 
Bifunctional dehydrogenase and ferrochelatase; involved in the biosynthesis of 
siroheme, a prosthetic group used by sulfite reductase; required for sulfate 
assimilation and methionine biosynthesis 
MBA1 39.8 
Membrane-associated mitochondrial ribosome receptor; forms a complex with 
Mdm38p that may facilitate recruitment of mRNA-specific translational 
activators to ribosomes; possible role in protein export from the matrix to 
inner membrane 
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KRE1 41.9 
Cell wall glycoprotein involved in beta-glucan assembly; serves as a K1 killer 
toxin membrane receptor 
YEL068C 42.1 Protein of unknown function; expressed at both mRNA and protein levels 
EDC3 45.03 
Non-essential conserved protein with a role in mRNA decapping; specifically 
affects the function of the decapping enzyme Dcp1p; mediates decay of the 
RPS28B mRNA via binding to both Rps28Bp (or Rps28Ap) and the RPS28B 
mRNA; mediates decay of the YRA1 mRNA by a different, translation-
independent mechanism; localizes to cytoplasmic mRNA processing bodies; 
forms cytoplasmic foci upon DNA replication stress 
YGR054W 45.1 
Eukaryotic initiation factor (eIF) 2A; associates specifically with both 40S 
subunits and 80 S ribosomes, and interacts genetically with both eIF5b and 
eIF4E; homologous to mammalian eIF2A 
DOT1 45.2 
Nucleosomal histone H3-Lys79 methylase; methylation is required for 
telomeric silencing, meiotic checkpoint control, and DNA damage response 
AMS1 45.2 
Vacuolar alpha mannosidase; involved in free oligosaccharide (fOS) 
degradation; delivered to the vacuole in a novel pathway separate from the 
secretory pathway 
NDE2 46.1 
Mitochondrial external NADH dehydrogenase; catalyzes the oxidation of 
cytosolic NADH; Nde1p and Nde2p are involved in providing the cytosolic 
NADH to the mitochondrial respiratory chain; NDE2 has a paralog, NDE1, that 
arose from the whole genome duplication 
YEL020C 46.8 
Protein of unknown function with low sequence identity to Pdc1p; mRNA 
identified as translated by ribosome profiling data 
YDR018C 46.8 
Probable membrane protein with three predicted transmembrane domains; 
similar to C. elegans F55A11.5 and maize 1-acyl-glycerol-3-phosphate 
acyltransferase; YDR018C has a paralog, CST26, that arose from the whole 
genome duplication 
ATG14 47 
Autophagy-specific subunit of phosphatidylinositol 3-kinase complex I; Atg14p 
targets complex I to the phagophore assembly site (PAS); required for 
localizing additional ATG proteins to the PAS; required for overflow 
degradation of misfolded proteins when ERAD is saturated; homolog of human 
Barkor; other members are Vps34, Vps15, and Vps30p 
MAK10 47 
Non-catalytic subunit of N-terminal acetyltransferase of the NatC type; 
required for replication of dsRNA virus; expression is glucose-repressible 
ITR1 47.1 
Myo-inositol transporter; member of the sugar transporter superfamily; 
expression is repressed by inositol and choline via Opi1p and derepressed via 
Ino2p and Ino4p; relative distribution to the vacuole increases upon DNA 
replication stress; ITR1 has a paralog, ITR2, that arose from the whole 
genome duplication 
YLR012C 47.2 Putative protein of unknown function; YLR012C is not an essential gene 
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RTF1 47.88 
Subunit of RNAPII-associated chromatin remodeling Paf1 complex; regulates 
gene expression by directing cotranscriptional histone modification, influences 
transcription and chromatin structure through several independent functional 
domains; directly or indirectly regulates DNA-binding properties of Spt15p and 
relative activities of different TATA elements; involved in transcription 
elongation as demonstrated by the G-less-based run-on (GLRO) assay 
SRS2 48.8 
DNA helicase and DNA-dependent ATPase; involved in DNA repair and 
checkpoint recovery, needed for proper timing of commitment to meiotic 
recombination and transition from Meiosis I to II; blocks trinucleotide repeat 
expansion; affects genome stability; disassembles Rad51p nucleoprotein 
filaments during meiotic recombination; functional homolog of human RTEL1 
YOL114C 49.3 
Putative protein of unknown function with similarity to human ICT1; has 
prokaryotic factors that may function in translation termination; YOL114C is 
not an essential gene 
YNL319W 51.2 
Dubious open reading frame; unlikely to encode a functional protein, based on 
available experimental and comparative sequence data; partially overlaps the 
verified gene HXT14 
SNC1 51.5 
Vesicle membrane receptor protein (v-SNARE); involved in the fusion between 
Golgi-derived secretory vesicles with the plasma membrane; proposed to be 
involved in endocytosis; member of the synaptobrevin/VAMP family of R-type 
v-SNARE proteins; SNC1 has a paralog, SNC2, that arose from the whole 
genome duplication 
UTR4 51.5 
Protein with sequence similarity to acireductone synthases; involved in 
methionine salvage; found in both the cytoplasm and nucleus 
NGR1 51.8 
RNA binding protein that negatively regulates growth rate; interacts with the 
3' UTR of the mitochondrial porin (POR1) mRNA and enhances its degradation; 
overexpression impairs mitochondrial function; interacts with Dhh1p to 
mediate POR1 mRNA decay; expressed in stationary phase 
MDS3 51.8 
Putative component of the TOR regulatory pathway; negative regulator of 
early meiotic gene expression; required, with Pmd1p, for growth under 
alkaline conditions; has an N-terminal kelch-like domain; MDS3 has a paralog, 
PMD1, that arose from the whole genome duplication 
AFG1 52.5 
Protein that may act as a chaperone for cytochrome c oxidase subunits; 
conserved protein; may act as a chaperone in the degradation of misfolded or 
unassembled cytochrome c oxidase subunits; localized to matrix face of the 
mitochondrial inner membrane; member of the AAA family but lacks a 
protease domain 
CAJ1 52.5 
Nuclear type II J heat shock protein of the E. coli dnaJ family; contains a 
leucine zipper-like motif, binds to non-native substrates for presentation to 
Ssa3p, may function during protein translocation, assembly and disassembly 
RAD23 52.6 
Protein with ubiquitin-like N terminus; subunit of Nuclear Excision Repair 
Factor 2 (NEF2) with Rad4p that binds damaged DNA; enhances protein 
deglycosylation activity of Png1p; also involved, with Rad4p, in ubiquitylated 
protein turnover 
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PHO8 53 
Repressible vacuolar alkaline phosphatase; regulated by levels of Pi and by 
Pho4p, Pho9p, Pho80p, Pho81p and Pho85p; dephosphorylates 
phosphotyrosyl peptides; contributes to NAD+ metabolism by producing 
nicotinamide riboside from NMN 
AGP2 54.8 
Plasma membrane regulator of polyamine and carnitine transport; has 
similarity to transporters but lacks transport activity; may act as a sensor that 
transduces environmental signals; has a positive or negative regulatory effect 
on transcription of many transporter genes 
SMY2 55.4 
GYF domain protein; involved in COPII vesicle formation; interacts with the 
Sec23p/Sec24p subcomplex; overexpression suppresses the temperature 
sensitivity of a myo2 mutant; similar to S. pombe Mpd2; SMY2 has a paralog, 
SYH1, that arose from the whole genome duplication 
MKT1 55.4 
Protein similar to nucleases that forms a complex with Pbp1p; complex may 
mediate posttranscriptional regulation of HO; involved in propagation of M2 
dsRNA satellite of L-A virus; allelic variation affects mitochondrial genome 
stability, drug resistance, and more; forms cytoplasmic foci upon DNA 
replication stress; localization to P-bodies under ethanol stress differs between 
strains 
PRE9 55.8 
Alpha 3 subunit of the 20S proteasome; the only nonessential 20S subunit; 
may be replaced by the alpha 4 subunit (Pre6p) under stress conditions to 
create a more active proteasomal isoform 
YLL059C 56.3 
Dubious open reading frame; unlikely to encode a functional protein, based on 
available experimental and comparative sequence data 
YGL138C 56.4 
Putative protein of unknown function; has no significant sequence similarity to 
any known protein 
ECL1 56.4 
Protein of unknown function; mitochondrial-dependent role in the extension of 
chronological lifespan; overexpression increases oxygen consumption and 
respiratory activity while deletion results in reduced oxygen consumption 
under conditions of caloric restriction; induced by iron homeostasis 
transcription factor Aft2p; multicopy suppressor of temperature sensitive hsf1 
mutant; induced by treatment with 8-methoxypsoralen and UVA irradiation 
BUD9 57.5 
Protein involved in bud-site selection; mutant has increased aneuploidy 
tolerance; diploid mutants display a unipolar budding pattern instead of the 
wild-type bipolar pattern, and bud at the distal pole; BUD9 has a paralog, 
BUD8, that arose from the whole genome duplication 
VAB2 57.7 
Subunit of the BLOC-1 complex involved in endosomal maturation; interacts 
with Vps21p-GFP; has potential role in vacuolar function, as suggested by its 
ability to bind Vac8p; likely member of; Vab2p-GFP-fusion localizes to 
cytoplasm in punctate pattern 
YGR153W 57.7 Putative protein of unknown function 
NPP2 57.8 
Nucleotide pyrophosphatase/phosphodiesterase; mediates extracellular 
nucleotide phosphate hydrolysis along with Npp1p and Pho5p; activity and 
expression enhanced during conditions of phosphate starvation; involved in 
spore wall assembly; NPP2 has a paralog, NPP1, that arose from the whole 
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genome duplication, and an npp1 npp2 double mutant exhibits reduced 
dityrosine fluorescence relative to the single mutants 
GPP2 57.8 
DL-glycerol-3-phosphate phosphatase involved in glycerol biosynthesis; also 
known as glycerol-1-phosphatase; induced in response to hyperosmotic or 
oxidative stress, and during diauxic shift; GPP2 has a paralog, GPP1, that 
arose from the whole genome duplication 
NUT1 58.2 
Component of the RNA polymerase II mediator complex; mediator is required 
for transcriptional activation and also has a role in basal transcription 
RMR1 58.8 
Protein required for meiotic recombination and gene conversion; null mutant 
displays reduced PIS1 expression and growth defects on non-fermentable 
carbon sources and minimal media; GFP-fusion protein localizes to both 
cytoplasm and nucleus 
HAT2 59 
Subunit of the Hat1p-Hat2p histone acetyltransferase complex; required for 
high affinity binding of the complex to free histone H4, thereby enhancing 
Hat1p activity; similar to human RbAp46 and 48; has a role in telomeric 
silencing 
CAD1 61 
AP-1-like basic leucine zipper (bZIP) transcriptional activator; involved in stress 
responses, iron metabolism, and pleiotropic drug resistance; controls a set of 
genes involved in stabilizing proteins; binds consensus sequence TTACTAA; 
CAD1 has a paralog, YAP1, that arose from the whole genome duplication 
ADE16 61.8 
Enzyme of 'de novo' purine biosynthesis; contains both 5-aminoimidazole-4-
carboxamide ribonucleotide transformylase and inosine monophosphate 
cyclohydrolase activities; ADE16 has a paralog, ADE17, that arose from the 
whole genome duplication; ade16 ade17 mutants require adenine and 
histidine 
GTT2 62.6 
Glutathione S-transferase capable of homodimerization; functional overlap 
with Gtt2p, Grx1p, and Grx2p; protein abundance increases in response to 
DNA replication stress 
YGL117W 62.8 Putative protein of unknown function 
GAT3 64 
Protein containing GATA family zinc finger motifs; involved in spore wall 
assembly; sequence similarity to GAT4, and the double mutant gat3 gat4 
exhibits reduced dityrosine fluorescence relative to the single mutants 
MFG1 66 
Regulator of filamentous growth; interacts with FLO11 promoter and regulates 
FLO11 expression; binds to transcription factors Flo8p and Mss11p; green 
fluorescent protein (GFP)-fusion protein localizes to the nucleus; YDL233W is 
not an essential gene 
LSB1 67.2 
Negative regulator of actin nucleation-promoting factor activity; interacts with 
Las17p, a homolog of human Wiskott-Aldrich Syndrome protein (WASP), via 
an N-terminal SH3 domain, and along with PIN3 cooperatively inhibits the 
nucleation of actin filaments; overexpression blocks receptor-mediated 
endocytosis; protein increases in abundance and forms nuclear foci in 
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response to DNA replication stress; LSB1 has a paralog, PIN3, that arose from 
the whole genome duplication 
YLL058W 68.3 
Putative protein of unknown function with similarity to Str2p; Str2p is a 
cystathionine gamma-synthase important in sulfur metabolism; YLL058W is 
not an essential gene 
PYC1 69 
Pyruvate carboxylase isoform; cytoplasmic enzyme that converts pyruvate to 
oxaloacetate; differentially regulated than isoform Pyc2p; mutations in the 
human homolog are associated with lactic acidosis; PYC1 has a paralog, PYC2, 
that arose from the whole genome duplication 
 
 
 
 
 
Table B.2.2 : Bee venom validated hits from yeast DAmP library screen 
 
Gene 
Name 
Residual 
Growth 
(%) 
Description 
SCL1 25 
Alpha 1 subunit of the 20S proteasome; involved in the degradation of 
ubiquitinated substrates; 20S proteasome is the core complex of the 26S 
proteasome; essential for growth; detected in the mitochondria 
DOP1 34.8 
Golgi-localized, leucine-zipper domain containing protein; involved in endosome 
to Golgi transport, organization of the ER, establishing cell polarity, and 
morphogenesis; detected in highly purified mitochondria in high-throughput 
studies 
UBA2 39 
Subunit of heterodimeric nuclear SUMO activating enzyme E1 with Aos1p; 
activates Smt3p (SUMO) before its conjugation to proteins (sumoylation), which 
may play a role in protein targeting; essential for viability 
RPN8 42.2 
Essential non-ATPase regulatory subunit of the 26S proteasome; has similarity 
to the human p40 proteasomal subunit and to another S. cerevisiae regulatory 
subunit, Rpn11p 
ERG26 52.8 
C-3 sterol dehydrogenase; catalyzes the second of three steps required to 
remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis 
NSL1 64 
Essential component of the MIND kinetochore complex; joins kinetochore 
subunits contacting DNA to those contacting microtubules; required for 
accurate chromosome segregation; complex consists of Mtw1p Including 
Nnf1p-Nsl1p-Dsn1p (MIND) 
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DBP10 75 
Putative ATP-dependent RNA helicase of the DEAD-box protein family; 
constituent of 66S pre-ribosomal particles; essential protein involved in 
ribosome biogenesis 
RPT4 76 
ATPase of the 19S regulatory particle of the 26S proteasome; one of six 
ATPases of the regulatory particle; involved in degradation of ubiquitinated 
substrates; contributes preferentially to ERAD; required for spindle pole body 
duplication; mainly nuclear localization 
 
Table B.3.1 : Bee pollen validated hits from yeast homozygous deletion library screen 
 
Systematic 
name 
Gene 
Name 
Growth 
Ratio 
Description 
YBR200W BEM1 1.56 
Protein containing SH3-domains; involved in establishing cell 
polarity and morphogenesis; functions as a scaffold protein for 
complexes that include Cdc24p, Ste5p, Ste20p, and Rsr1p 
YKL081W TEF4 1.27 
Gamma subunit of translational elongation factor eEF1B; 
stimulates the binding of aminoacyl-tRNA (AA-tRNA) to ribosomes 
by releasing eEF1A (Tef1p/Tef2p) from the ribosomal complex 
YER111C SWI4 1.22 
DNA binding component of the SBF complex (Swi4p-Swi6p); a 
transcriptional activator that in concert with MBF (Mbp1-Swi6p) 
regulates late G1-specific transcription of targets including cyclins 
and genes required for DNA synthesis and repair; Slt2p-
independent regulator of cold growth; acetylation at two sites, 
K1016 and K1066, regulates interaction with Swi6p 
 
Table B.3.2 : Bee pollen validated hits from yeast DAmP library screen 
 
Systematic 
name 
Gene 
Name 
Growth 
Ratio 
Description 
YGL225W VRG4 1.96 
Golgi GDP-mannose transporter; regulates Golgi function and 
glycosylation in Golgi; VRG4 has a paralog, HVG1, that arose from 
the whole genome duplication 
YDR301W CFT1 1.84 
RNA-binding subunit of the mRNA cleavage and polyadenylation 
factor; involved in poly(A) site recognition and required for both 
pre-mRNA cleavage and polyadenylation, 51% sequence similarity 
with mammalian AAUAA-binding subunit of CPSF 
YIL063C YRB2 1.69 
Protein of unknown function; involved in nuclear processes of the 
Ran-GTPase cycle; involved in nuclear protein export; contains Ran 
Binding Domain and FxFG repeats; interacts with Srm1p, GTP-
Gsp1p, Rna1p and Crm1p; relocalizes to the cytosol in response to 
hypoxia; not essential for viability 
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YIR022W SEC11 1.6 
18kDa catalytic subunit of the Signal Peptidase Complex (SPC); the 
Signal Peptidase Complex cleaves the signal sequence of proteins 
targeted to the endoplasmic reticulum; other members are Spc1p, 
Spc2p, Spc3p, and Sec11p 
YFL005W SEC4 1.6 
Rab family GTPase; essential for vesicle-mediated exocytic 
secretion and autophagy; associates with the exocyst component 
Sec15p and may regulate polarized delivery of transport vesicles to 
the exocyst at the plasma membrane 
YDL017W CDC7 1.43 
DDK (Dbf4-dependent kinase) catalytic subunit; required for origin 
firing and replication fork progression in mitotic S phase through 
phosphorylation of Mcm2-7p complexes and Cdc45p; kinase 
activity correlates with cyclical DBF4 expression; required for pre-
meiotic DNA replication, meiotic DSB formation, recruitment of the 
monopolin complex to kinetochores during meiosis I and as a 
gene-specific regulator of the meiosis-specific transcription factor 
Ndt80p 
YKL012W PRP40 1.35 
U1 snRNP protein involved in splicing; interacts with the 
branchpoint-binding protein during the formation of the second 
commitment complex 
YMR094W CTF13 1.35 
Subunit of the CBF3 complex; CBF3 binds to the CDE III element of 
centromeres, bending the DNA upon binding, and may be involved 
in sister chromatid cohesion during mitosis 
YJL011C RPC17 1.34 
RNA polymerase III subunit C17; physically interacts with C31, 
C11, and TFIIIB70; may be involved in the recruitment of pol III by 
the preinitiation complex; protein abundance increases in response 
to DNA replication stress; relocalizes to the cytosol in response to 
hypoxia 
YMR239C RNT1 1.34 
Nuclear dsRNA-specific ribonuclease (RNase III); involved in rDNA 
transcription, rRNA processing and U2 snRNA 3' end formation by 
cleavage of a stem-loop structure at the 3' end of U2 snRNA; 
involved in polyadenylation-independent transcription termination; 
involved in the cell wall stress response, regulating the degradation 
of cell wall integrity and morphogenesis checkpoint genes 
 
 
